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ABSTRACT 
Metastatic melanoma is the major cause of skin cancer death, and the annual incidence of 
melanoma continues to increase. Despite the impressively high rates of response to 
BRAF inhibitors in patients with melanomas harboring BRAF mutations, most of these 
patients eventually relapse after developing resistance to the drug, due in part to 
secondary mutations in NRAS. Although NRAS mutation is the second most common 
genetic mutation in melanoma patients (after BRAF mutation), there is currently no 
treatment option that targets NRAS-mutated melanomas. Previous reports have 
demonstrated the sensitivity of cancer cell lines carrying RAS mutations to apoptosis 
initiated by inhibition of protein kinase C delta (PKC8), suggesting the possible 
association between RAS mutational status and sensitivity to PKCo inhibition. I therefore 
hypothesized that PKC8 inhibitors might also be cytotoxic in melanomas with primary or 
VI 
acquired NRAS mutations. In this project, the effect of PKC() inhibition, and the efficacy 
of a new PKCcS inhibitor, BJE6-1 06 (B 1 06), in melanoma were investigated. Inhibition of 
PKC() inhibited the growth of multiple human melanoma cell lines carrying NRAS 
mutations, and induced apoptosis mediated by terminal caspase activation. Analysis of 
the molecular mechanisms demonstrated activation of the JNK pathway after PKC() 
inhibition, leading to the activation (phosphorylation) of H2AX, a histone H2A variant. 
Activation ofH2AX was attenuated when JNK1/2levels were repressed, indicating that 
H2AX activation is mediated by the JNK pathway in response to PKC() inhibition. 
Consistent with recent reports on the apoptotic role ofphospho-H2AX, knockdown of 
H2AX prior to PKCcS inhibition mitigated the induction of caspase-dependent apoptosis. 
To explore the potential ofB106 further, melanoma cell lines harboring BRAF mutations 
that had evolved resistance to a BRAF inhibitor, PLX4032 (vemurafenib ), were 
developed. B 106 effectively induced cytotoxicity in these cells, suggesting the potential 
clinical application of targeting PKC() in patients who have relapsed following treatment 
with PLX4032. Taken together, this work suggests that inhibition ofPKCcS causes 
caspase-dependent apoptosis in melanomas with NRAS mutations and in PLX4032-
resistant BRAF mutant melanomas. This apoptosis is mediated via activation of the JNK-
H2AX pathway, which involves a novel role for phospho-H2AX in the execution of 
apoptosis. 
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Introduction 
Melanoma is one of the three major types of skin cancers that originate within the 
epidermis, which sustains the most damage from the sun. Skin cancers are subcategorized 
based on the types of cells that the cancers originated from: basal cell carcinomas, 
squamous cell carcinomas and melanomas. Basal cell and squamous cell carcinomas 
(collectively referred to as non-melanoma skin cancers) are more prevalent, but highly 
curable. Conversely, melanomas, originating in melanocytes, account for less than 5% of 
skin cancers; however, they are responsible for more than 75% of estimated skin cancer 
deaths in 2012, and more strikingly, the incidence rate has been increasing for the last 30 
years (1 ). Although melanomas can be curable if detected at their earliest stages and 
treated properly, they are more metastatic than other skin cancer types: for localized 
melanoma (84% of cases), the 5-year survival rate is 98%; survival declines to 62% and 
15% for regional and distant stage disease, respectively (1). 
Advanced melanomas are treated with surgery, chemotherapy, and/or radiation 
therapy. Chemotherapy has not made a significant impact on survival in metastatic 
melanoma for decades, although some protocols achieved improved response rates. In 
addition to these conventional treatment options, the Food and Drug Administration 
(FDA) approved two targeted therapies for metastatic melanomas in 2011. lpilimumab is 
an immunotherapy that activates cytotoxic T-lymphocytes (CTL), by blocking CTL 
antigen 4 (CTLA-4), for destruction of cancerous cells (2). Ipilimumab was targeted for 
melanoma because it is one of the most immunogenic cancers, as indicated by the 
presence of tumor infiltrating lymphocytes (2). Although the adverse effects of the 
treatment are highly manageable, the clinical benefit remains relatively mild: the 
response rate (complete and partial responses) was limited to 1 0-15% and overall survival 
was extended only by an average of a few months (2). 
The other FDA-approved therapy, vemurafenib (also known as PLX4032), was 
developed to target the genetic background of melanoma. Melanoma is highly-dependent 
on the Ras/Raf/MEK/ERK pathway, one of the three major pathways of mitogen-
activated protein kinase (MAPK) pathways. Melanoma is therefore frequently the target 
disease area of investigational drugs targeting B-Raf and MEK which are currently in 
clinical trials (3). Physiologically, upon the arrival of extracellular stimuli, Ras GTPase 
family proteins (K-Ras, N-Ras and H-Ras) are activated and induce a series of kinase 
chain-reactions, including the Raf/MEK/ERK pathway (Figure 1). The activation of the 
Raf/MEK/ERK pathway evokes critical changes in cellular activities, such as cell 
proliferation and survival in normal cells; conversely, uncontrolled activity of the Ras 
proteins or the Raf/MEKIERK pathway can result in aberrant proliferation, migration, 
morphological changes and epithelial-mesenchymal transition (EMT), leading to 
malignant transformation and progression of cancers. In melanoma, the most common 
genomic mutations occur in BRAF (one ofthe three Rafisoforms) which are observed in 
50-70% of melanoma cases, while NRAS mutations, the second most frequent in 
melanoma, account for 15-30% (4-6). While BRAF and NRAS mutations are considered 
to be mutually exclusive, constitutive hyperactivation of ERK signaling is the common 
consequence since both molecules lie upstream of the ERK-MAPK pathway (6). 
Vemurafenib is a selective B-Rafinhibitor which preferentially inhibits the V600E 
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mutant form ofB-Raf over wild-type and was approved for late-stage melanoma patients 
with BRAF-V600E mutation. In clinical trials, vemurafenib achieved significant response 
rates and tumor regression in patients with BRAF-V 600E mutation compared to 
conventional treatment; however, responders eventually and inevitably become resistant 
to this drug and relapse (7). As discussed in Chapter 3 in more detail, one of the proposed 
mechanisms of acquired resistance to vemurafenib is development of secondary 
mutations in the NRAS gene and reactivation ofERK-MAPK signaling, whose 
suppression was originally the goal of vemurafenib action (8). 
Although these first targeted therapies approved for melanoma present great 
potential, there are remaining obstacles to be addressed: low response rates to ipilimumab 
and recurrence due to drug resistance to vemurafenib. Another remaining problem in 
melanoma is the absence of targeted therapies for non-BRAF-mutant-melanomas. 
V emurafenib was approved specifically for the patients with the BRAF-V 600E mutation, 
while it is still difficult to predict who would respond to treatment with ipilimumab. Even 
with the emergence of these promising new drugs, these issues still place advanced 
melanomas among notoriously difficult cancers to treat and new treatment options are 
urgently needed. Moreover, mutation ofBRAF was reported to be associated with 
enhanced and selective sensitivity to MEK inhibition in comparison to cells harboring 
either a wild-type BRAF or a RAS mutation, even though target of action of MEK 
inhibitors does not directly involve BRAF mutations (9). In fact, many investigational 
MEK inhibitors currently in clinical trials are being tested against BRAF-mutant type 
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melanomas. This current situation further underlines the need for new strategies, 
especially for non-BRAF-mutant-melanomas. 
Previous reports demonstrated the sensitivity of pancreatic cancer cell lines 
carrying oncogenic KRAS mutations to apoptosis initiated by inhibition of protein kinase 
C delta (PKC8) (1 0). Although PKC8 belongs to the PKC family of serine/threonine 
protein kinases, which is involved in the regulation of a wide variety of important cellular 
functions, PKC8 is not required for survival of normal, non-cancerous cells, making it a 
potential therapeutic target that can be selective against cancer cells (11 ). Considered 
together with the mutation profile of melanoma and the current obstacles to the 
melanoma therapies, these observations led me to the hypothesis that PKC8 can be a 
potential therapeutic target in melanomas with an original NRAS mutation or secondary 
mutation resulting from drug resistance, and that pharmacological inhibitors of PKC8 
might provide a clinical benefit to those types of melanomas. This dissertation presents 
the effect of PKC8 inhibition on cell growth suppression and the efficacy of PKC8 
inhibition in melanomas which remain insensitive to the currently-available targeted 
therapies, and proposes a molecular mechanism of apoptosis and cancer growth 
inhibition, which involves a novel role for phospho-H2AX. 
The dissertation consists of three chapters. Chapter 1 introduces the PKC8 
inhibitors used in the project, including BJE6-1 06 (B 1 06), which has been developed in 
our lab, and their effects on cell growth inhibition in melanoma with NRAS mutations. It 
also demonstrates the mechanism of growth inhibition caused by inhibition ofPKC8: 
caspase-dependent apoptosis. Chapter 2 provides the molecular mechanism by which 
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PKCo inhibition leads to apoptosis through activation of the stress response signaling 
JNK pathway. JNK activation provoked by inhibition ofPKCo is directly linked to the 
activation of histone H2A variant H2AX, which is a novel mechanism of apoptosis 
induction. Chapter 3 focuses on the effect ofPKCo inhibition on melanoma cell lines 
carrying BRAF mutations which developed resistance to vemurafenib, as well as the 
mechanisms of resistance in these particular sub cell lines. These PLX4032-resistant cells 
responded to B106 in manner similar to the NRAS-mutant melanoma cells, which might 
suggest a method to screen for types of cancers that are potentially susceptible to a 
therapy using PKCo inhibitors, for future clinical application. The dissertation is 
concluded with the discussion including the significance of this work and future 
directions beyond the studies presented. 
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Figure 1: Ras/Raf/MEKIERK pathway in melanoma. Melanoma is highly-dependent 
upon Ras/Raf/MEK/ERK signaling for survival. BRAF is the most frequently mutated 
gene in melanoma and genomic mutations in BRAF are observed in 50-70% of 
melanoma cases. NRAS mutations account for 15-30% of melanomas. These mutations 
occur mutually exclusively, but both cause constitutive activation ofERK signaling. 
Vemurafenib, approved by FDA in 2011 for metastatic melanomas, preferentially inhibits 
the V600E mutant form ofB-Raf over wild-type, which provides cancer-selectivity to the 
therapy. 
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Materials and Methods 
Reagents 
BJE6-106 and BJE6-154 were designed by Dr. Douglas V. Faller with the scheme stated 
in Chapter land synthesized by Dr. Robert M Williams (Colorado State University, Fort 
Collins, CO). Rottlerin, PLX4032 (vemurafenib), U0126 and propidium iodine, RNase A 
were purchased from Axxora, LC Labs, Promega, Sigma and Fisher Bio Reagents 
respectively. Z-VAD-FMK was purchased from R&D Systems and Enzo Life Sciences. 
Antibodies against phospho-SAPK/JNK (Thr 183/Tyr 185) ( #4668), SAPK/JNK ( #9252), 
phospho-Histone H2A.X (Ser 139) (#2577), Histone H2A (#2578), phospho-
SEK1/MKK4) (#4514), SEK1/MKK4 (#9152), phospho-MKK7 (Ser271/Thr275) 
(#4171), MKK7 (#4172), phospho-c-Jun (Ser63) (#9261), c-Jun (#9165), phospho-
ERKl /2 (Thr202/Tyr204) (#4370), phospho-Akt (Ser473) (#4060), phospho-p38 
(Thr180/Tyr182) (#4511), p38 (#9212), phospho-c-Raf (Ser338) (#9427) and phospho-B-
Raf (Ser445) (#2696) were purchased from Cell Signaling Technologies. Antibodies 
against ERKl (K-23), Aktl(B-1), B-Raf(C-19), Raf-1 (C-12) and N-Ras (F155) are 
purchased from Santa Cruz Biotechnology. Antibodies against Ras (#610001) and PKCo 
(#610398) were purchased from BD Biosciences. Antibodies against a-Tubulin 
(#T6074), P-Actin (#A1978) and GAPDH (#G8795) were purchased from Sigma-
Aldrich. Plasmids pBabe-N-Ras-61K and pBabe-Puro-BRAF-V600E were purchased 
from Addgene. ON-TARGETplus SMART pool siRNA against JNK1 (L-003514), JNK2 
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(L-003505) and H2AX (L-011682) were purchased from Dharmacon. Silencer Select 
siRNA against PKC8 (PRKCD) was purchased from Ambion. 
Cell culture, siRNA transfection, plasmid stable transfection & PLX4032-resistant 
sub cell lines 
SBcl2 was obtained from Department of Dermatology, Boston University School of 
Medicine (Boston, MA). A375 and SKMEL5 were obtained from Dr. Remco Spanjard. 
WM1366, WM1361A, WM852, FM28, FM6, SKMEL2 and SKMEL28 were obtained 
from Dr. Anurag Singh (Boston University School of Medicine, Boston, MA). NIH-3T3 
was purchased from ATCC. SBcl2, and A375 and its derivative lines were maintained in 
Dulbecco' s modified Eagle ' s medium (DMEM) supplemented with 10% fetal bovine 
serum. SKMEL5 was maintained in minimum essential medium (MEM) supplemented 
with 10% fetal bovine serum. NIH-3T3 and its derivative lines were maintained in 
DMEM supplemented with 10% donor calf serum. All media were additionally 
supplemented with L-glutamine 2mM, penicillin 100 units/ml, and streptomycin 
1 OOJ.tg/ml. siRNA transfection was performed by reverse transcription using 
Lipofectamine RNAiMax (Invitrogen) according to the product protocol, and media was 
changed the following day oftransfection. NIH-NRAS and NIH-BRAF cell sublines 
were established by stably transfection with pBabe-N-Ras-61K and pBabe-Puro-BRAF-
V600E, respectively, and selection in puromycin-containing medium (2.5J.tg/ml). 
PLX4032-resistant cell sublines were established according to the method described in 
(8). Briefly, A375 and SKMEL5 cells were plated at low cell density and treated with 
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PLX4032 at l~M or 0.5~M, respectively. The concentration ofPLX4032 was gradually 
increased up to 4~M (A375) or 2~M (SKMEL5) over the course of 3-4 week period, and 
clonal colonies were picked up. Derived sublines of A375 and SKMEL5 have been 
maintained in PLX4032-containing medium at 1-2~M (A375) or 0.5~M (SKMEL5) since 
selection. 
Cell proliferation & Caspase assays 
Cell proliferation assays (MTS assay) and caspase assays were performed with CellTiter 
96 AQueous Non-Radioactive Cell Proliferation Assay kit and Caspase-Glo 3/7 Assay 
Systems (Promega) according to the product protocols. Briefly, for the assays employing 
inhibitors, cells were plated in a 96-well plate (500-4000 cells per well depending on the 
cell lines and duration of the experiment), treated with inhibitors 24 hours later and 
cultured for the durations indicated in the individual figure legends. For the assays 
employing siRNA, cells were plated the day of siRNA transfection, cultured for the 
duration indicated in the figure legends, and if indicated, treated with inhibitors. After the 
indicated treatment time, assay reagent was added and cell plates were incubated for 1 
hour at 37°C (MTS assay) or 30 minutes at RT (caspase assay) . Absorbance at 490nm 
(MTS assay) or luminescence (caspase assay) were measured using microplate readers 
for quantification. 
Clonogenic colony assay 
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For the experiments depicted in Figure 7, cells were treated with drugs for the time 
indicated in the figure, and then the same number of viable cells from each treatment was 
replated at the low cell density and cells were cultured in normal medium for 8 days, by 
which time colony formation was quantitated. For the experiments depicted in Figure 28, 
cells were plated at low density and treated with inhibitors 24 hours later. Cells were 
cultured in inhibitor-containing medium for the next 8 days. Cell colonies were stained 
with ethidium bromide for visualization on an ImageQuant LAS 4000 (GE Healthcare) 
and number of colonies counting. 
DNA fragmentation 
Cells were harvested and fixed in 1 m1 of a 35% ethanol/DMEM solution at 4°C for 30 
min. Cells were then stained with a solution containing 25f.!g/ml ofpropidium iodide/ml 
and 50f.lg/ml ofRNase A in PBS and incubated in the dark at 37°C for 30 min for flow 
cytometric analysis. The proportion of cells in the sub-G 1 population, which contain a 
DNA content of less than 2N (that is, fragmented DNA), was measured as an indicator of 
apoptosis. 
Immunoblotting & Ras activity assay 
Whole celllysates were prepared in a buffer containing 20mM Hepes (pH 7.4), 10% 
glycerol, 2mM EDTA, 2mM EGTA, 50mM ~-glycerophosphate and 1% Triton-X100, 
1mM dithiothreitol (DTT) and 1mM sodium vanadate, supplemented with Halt Protease 
and Phosphatase Inhibitor Cocktail (lOOX) (Thermo Scientific). For Ras activity assay, 
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whole celllysates were prepared in a buffer containing 25mM Hepes (pH 7.4), 150mM 
NaCl, 1mM EDTA, 10mM MgC12, 25mM NaF, 10% glycerol, 0.25% sodium 
deoxycholate, 1% Nonidet P-40 and 1mM sodium vanadate, supplemented with Halt 
Protease and Phosphatase Inhibitor Cocktail (1 OOX), and activated Ras proteins were 
pulled down from the whole celllysates using 1 Of..tg of agarose-conjugated Raf-1 Ras 
binding domain peptide (#14-278, Millipore) according to the product protocol. Lysates 
were subjected to SDS-P AGE and transferred to nitrocellulose membranes. Membranes 
were blocked at RT for 1-1.5h with 5% BSA or 5% non-fat dry milk in TBS-T and 
probed with the appropriate primary antibodies (1 :500-1:1 0,000) overnight. After 
washing, the blots were incubated with horseradish peroxidase-conjugated secondary 
antibodies (1 :2000-1:1 0,000) and visualized using the ECL system (Amersham 
Biosciences) on an ImageQuant LAS 4000. 
Quantitative real-time PCR 
RNA is extracted with RNeasy Mini kit purchased (Qiagen) according to the product 
protocol. 1f..tg of RNA was used to synthesize eDNA in a 20f..tl reaction volume 
employing SuperScript III First-Strand Synthesis System (Invitrogen) or QuaniTect 
Reverse Transcription Kit (Qiagen) according to the product protocol. Quantitative real-
time PCR was performed with SYBR Green PCR Master Mix (Applied Biosystems) 
according to the product protocol. Briefly, eDNA was diluted to a final concentration of 
25ng per reaction, added to a primer set (5f.!M) and SYBR Green PCR Master Mix to a 
final volume of reaction mixture of20f..tl, and run on an Applied Biosystems 7500 Fast 
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Real-Time PCR system using the following thermal cycling protocol: 50°C for 2 min, 
95°C for 10 min, and 40 cycles of95°C for 15 sec and 60°C for 1 min. The relative 
amount of an mRNA of interest was calculated by normalizing the Ct value of the mRNA 
to the Ct ofthe internal control. Primer sequences were: H2AX Forward: 5'-
CAACAAGAAGACGCGAATCA-3' , H2AX Reverse: 5'-
CGGGCCCTCTTAGTACTCCT-3', B-actin Forward: 5'-
GCTCGTCGTCGACAACGGCTC-3', B-actin Reverse: 5'-
CAAACATGATCTGGGTCATCTTCTC-3'. 
Mouse tumor xenograft model 
Prior to the experiment to test B106 for anti-tumor efficacy in mice, tumors were grown 
and harvested from donor animals for future implantation. Athymic nude mice 
(Crl:NU(NCr)-Foxn1nu homozygous, Charles River) were injected subcutaneously with 
3 x 1 06 cells of the SBcl2 cell line and tumors were grown. Approximately 3 months 
later, these tumors were harvested, dissected into small blocks (approximately 3 mm3) 
and frozen in 10% DMSO/medium. For the xenograft study, tumor blocks were 
implanted subcutaneously into 12 mice and 8 days later, when tumor growth was 
apparent, dosing was started. 6 mice were administered vehicle (DMSO) intraperitoneally 
and the other 6 mice were administered B106 (40mg/kg) daily for 12 consecutive days. 
Tumor size was documented daily and tumor growth rate was calculated. 
Genomic mutation analysis 
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Genomic mutations in NRAS codon 61 and BRAF codon 600 in SBcl2, A375 and 
SKMEL5 and their drug-resistant sublines were analyzed by Genewiz (Figure 24A, Table 
1). Genomic mutations in NRAS codon 61 in FM6, FM28, SKMEL2, WM1366, 
WM1361A and WM852 were analyzed by Dr. Anurag Sing's Lab (Boston University 
School ofMedicine, Boston, MA). 
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Chapter 1: PKCa inhibition causes growth inhibition in melanoma with 
NRAS mutation by inducing caspase-dependent apoptosis 
1-1. Introduction 
PKC8 belongs to the PKC family of serine/threonine protein kinases, which is 
involved in diverse cellular functions, such as cell proliferation, tumor promotion, 
differentiation and apoptotic cell death (12). The PKC family is categorized into three 
subfamilies based on structural, functional and biochemical differences, and activators: 
the classical/conventional PKCs (cPKCs: a, ~1, ~II, y), the novel PKCs (nPKCs: 8, E, 8, 
J..L), and the atypical PKCs (aPKCs: s, A.). The novel PKCs that include PKC8 are 
characteristically activated by diacylglycerol (DAG) and are independent of the second 
messenger Ca2+. PKC8 is a 77.5 kDa protein, consisting of 676 amino acids and widely 
expressed among tissues (12). In its inactive state, PKC8 is folded at the linker region 
between theN-terminal regulatory domain and the C-terminal catalytic domain and auto-
inhibited. Upon the binding of DAG to the regulatory domain or phosphorylation on 
threonine/serine residues, PKC8 changes its conformation into the active state, in which 
the substrate binding site in the catalytic domain is fully exposed (13). Conversely, 
phosphorylation of certain other tyrosine residues exerts an inhibitory effect on its kinase 
activity: in some cases, phosphorylation of the same residue was reported to be either 
stimulatory or inhibitory depending on the context (12). While this apparent conflict 
implies a complexity in the regulation of this protein in different circumstances, it also 
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might be attributed to the fact that the structural information was primarily obtained from 
in vitro studies. It is possible that this might not completely reflect the physiological 
condition. 
PKC8 functions as either a pro- and anti-apoptotic regulator, depending on 
cellular context, such as stimuli/tissue types or its subcellular localization. Most studies 
have described it as pro-apoptotic. The existing research on the pro-apoptotic functions of 
PKC8 can be categorized into three groups based on the following parameters: 1) 
proteolytic cleavage ofPKC8 by caspase 3, 2) subcellular localization ofPKC8, and 3) 
induction/suppression of other molecules by PKC8-dependent phosphorylation. The 
former two events were reported to activate PKC8 under pro-apoptotic environmental 
conditions, whereas the third category regulates certain downstream effectors of activated 
PKC8, which activate the apoptotic cascade in the cell. Proteolytic cleavage of the linker 
region between the regulatory and catalytic domains by caspase 3, which exposes the 
substrate binding site in the catalytic domain, is another way of activating PKC8, in 
addition to the conformational change introduced by DAG binding or phosphorylation as 
mentioned above: in contrast, however, proteolytic activation is exclusive to the pro-
apoptotic function and irreversible, so that it is believed to occur when cells are destined 
for apoptosis (13). Translocation of cytosolic PKC8 to multiple subcellular organelles has 
been reported, possibly in a tissue- or stimulus dependent manner, but the mitochondria 
and nuclei appear to be the major destinations. Translocated PKC8 phosphorylates 
apoptotic regulators in those compartments. While translocation can occur with or 
without proteolytic cleavage by caspase 3, translocation can also trigger proteolytic 
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cleavage (13, 14) (Figure 2). There are various downstream targets ofpro-apoptotic 
PKC8 reported which appear to also be subject to cellular contexts, including MAPK 
family (ERK, p38, JNK), Bcl-2 family(15-18), the inhibitor ofapoptosis (lAP) family 
(19) or p53 (15, 20) (Figure 2). Among MAPK signaling pathways, stress-activated 
protein kinase/c-Jun N-terminal kinase (SAPK/JNK) and p38 are known to mediate the 
stress response signaling. PKC8 has been reported to provoke apoptosis through 
activation ofp38 or JNK (17, 18, 21-27). On the other hand, both stimulation and 
suppression of ERK signaling, often known as a pro-survival signaling, downstream of 
activated PKC8, was shown to cause apoptosis (28, 29). Tumor suppressor p53-mediated 
apoptosis and cell cycle arrest through increased expression of cyclin-dependent kinase 
(CDK) inhibitors p21 Cipi/WAFI and p27 Kip! have also been reported to occur downstream 
of activated PKC8 (20, 30-33). 
Although PKC8 is mainly known as a pro-apoptotic regulator, the anti-
apoptotic/pro-survival function of PKC8 has also been documented in multiple studies. 
Increased expression ofPKC8 has been observed in various types of cancers (34-36). In 
B cell chronic lymphocytic leukemia (B-CLL) cells isolated from patient blood, PKC8 
was activated and its inhibition strikingly induced apoptosis in contrast to normal 
peripheral blood B cells (37). The role ofPKC8 in anti-apoptotic/pro-survival signaling 
has been reported in non-small cell lung cancer (NSCLC), pancreatic, breast and colon 
cancer cells, neutrophils, thyroid cells, inslin-secreting cells (35, 36, 38-42). In these 
studies, PKC8 was implicated as an early regulator in the anti-apoptotic/pro-survival 
signaling cascades through induction or suppression of downstream substrates (Figure 
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2). Pro-survival signaling pathways involving ERK, AKT or NF-KB were most frequently 
indicated as PKC8 downstream targets among these studies, whereas one group reported 
PKC8 downregulation increased ERK activity and caused apoptosis in a breast cancer 
cell line (37, 40-46). Knockdown ofPKC8 was reported to induce JNK-mediated 
apoptosis via intermediate upregulation of PKCa and PKC~ in prostate cancer cell lines 
( 47). Interestingly, glycogen synthase kinase-3 (GSK3) was implicated to be either an 
upstream or downstream regulator ofPKC8 (40, 42). Expression ofFLICE-like inhibitory 
protein (FLIP), an endogenous caspase inhibitor, and ciAP2, a member of inhibitor of 
apoptosis (lAP) family, were induced by activation ofPKC8 (45, 46). PKC8 facilitates 
proliferation of insulin-secreting cells by promoting nuclear export of p21 Cip l/W AFl ( 48). 
PKC8 is also implicated in metastasis of melanoma. Overexpression of PKC8 
increased the metastatic potential of murine BL 16 mouse melanoma cells, and elevated 
expression of PKC8 and PKCa was shown to be responsible for integrin-mediated 
invasion of melanoma cells (49, 50). In addition, several studies demonstrated that 
inhibition of PKC8 sensitized cells to apoptosis induced by chemotherapeutic agents, 
such as trastuzumab, cisplatin or doxorubicin analogs, or TNF-related apoptosis-inducing 
ligand (TRAIL) through inhibition ofERK, AKT or NF-KB pathways (35, 44, 51, 52). 
Our previous studies demonstrated the sensitivity of pancreatic cancer cell lines 
carrying oncogenic KRAS mutations to apoptosis initiated by inhibition of PKC8 by 
means of a chemical inhibitor or RNA interference (RNAi) (1 0). Oncogenic mutations of 
Ras proteins are found in up to 30% of all human tumors, and are particularly frequent in 
those types of cancers with the highest mortality rates, such as lung, colorectal and 
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pancreatic cancers and melanomas. For this reason, pharmacological interventions of 
oncogenic Ras proteins have long been sought; however, direct targeting ofRas proteins 
themselves was unexpectedly challenging and Ras proteins are now widely considered to 
be "undruggable" targets (please see my recent review (3)). Meanwhile, the emerging (or 
rediscovered) strategies variously termed "synthetic lethality" and "non-oncogene 
addiction" have produced a framework for the development of indirect approaches to 
targeting mutant Ras in cancer cells. Two genes are in a so-called "synthetic lethal" 
interaction if a mutation of either gene alone is compatible with viability but 
simultaneous mutations of both genes lead to cell death (53-55). Thus, inhibition of a 
synthetic lethal interactor ofRas theoretically kills only tumor cells with a mutated RAS 
gene without affecting nornal cells. Similarly, "non-oncogene addiction" describes the 
situation in which transformation of a cell (whether by a known oncogene or unknown 
mechanisms) renders it dependent upon a normally non-essential protein for survival 
(56). These concepts have provided a new approach to target oncogenic Ras indirectly: 
that is, to discover synthetic lethal interactors, or critical "non-oncogenes," which are 
more druggable than Ras, and then develop therapeutic methods to target these 
interactors. Importantly for this new approach, PKC() is not required for the proliferation 
or survival of normal cells, and PKC5-null animals develop normally and are fertile, 
suggesting the potential tumor-specificity of a PKC5-targeted approach (11). In the 
previous work mentioned above, inhibition of PKC<> induced apoptosis in pancreatic 
cancer cell lines with activating KRAS mutations at least in part through suppression of 
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AKT signaling, and "Ras-dependency" in the tumors was not required for the cytotoxic 
effects (1 0, 57). 
In this chapter, the project hypothesis, which postulated potential cytotoxic effects 
ofPKC8 inhibition in melanoma with NRAS mutation, was tested using multiple 
modalities of PKC8 inhibition, including chemical inhibitors, such as a commercially 
available PKC8 inhibitor and a novel inhibitor that has been developed in our lab, and 
siRNA in multiple melanoma cell lines with NRAS-Q61 mutations. Chapter 1 also 
demonstrates the efficacy of the new inhibitor and the mechanism of cell growth 
inhibition induced by PKC8 inhibition. 
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Figure 2: Complexity of PKC() regulation, downstream effectors and outcome. 
PKC8 is activated by proteolytic cleavage, changes in subcellular localization or 
phosphorylation of tyrosine residues. Activation ofPKC8 is involved in multiple cellular 
activities including apoptosis, cell cycle regulation or DNA-damage response through 
stimulation or suppression of a variety of signaling pathways. 
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1-2. Results 
Characteristics of novel PKC() inhibitor BJE6-106 (B106) 
The rationale for PKC8 as a therapeutic target in cancer-targeted therapies is 
supported by the preceding reports: 1) its inhibition preferentially inhibits the growth of 
pancreatic cancer cells with KRAS mutation, which is prominent in many types of 
cancers with particularly high prevalence and mortality rates, and inhibits cells into 
which activated K-Ras or H-Ras have been introduced, as well as a variety of other tumor 
cell lines with RAS mutations (1 0, 58), and 2) PKC8 is not required for the proliferation 
or survival of normal cells (56). Although commercially-available rottlerin has been 
extensively utilized as a PKC8-selective inhibitor in many fields of research , its 
exclusive specificity against PKC8 has been questioned in a recent study (59). Some PKC 
isozymes are required for normal physiological functions and inhibition of such isozymes 
by a non-selective PKC8 inhibitor could damage normal cells (60). We therefore pursued 
development of a more potent PKC8 inhibitor with higher PKC8 selectivity. In the effort 
to seek next generation PKC8-selective inhibitors, a number of compounds were 
designed based on the structure of rottlerin (for isozyme specificity) and the pan-PKC 
inhibitor staurosporine (for potency). Among 36 novel compounds synthesized, BJE6-
1 06 (B 1 06), showed the greatest potency in different types of cancer cell lines including 
melanoma, prostate cancer, triple-negative breast cancer, and pancreatic cancer (data not 
shown). Figure 3 shows the chemical structures of the PKC8 inhibitors used in this study 
(rottlerin and B106). BJE6-154 (B154) was among the least potent of36 compounds 
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studied and is being used as the negative control with minimal inhibitory activity against 
PKC8. In vitro kinase assays demonstrated IC5o value of 50nM for B 106 against PKC8, 
and verified a 1000-fold PKC() selectivity over PKCa (Table 1). To further validate the 
target specificity ofB106, in vitro kinase assays in which B106 is tested against a panel 
of kinases are being planned in the near future. All three compounds were dissolved in 
DMSO for the following studies. 
Changes in cell morphology induced by rottlerin or B 1 06 treatment in SBcl2, a 
melanoma cell line with NRAS-Q61K mutation, were compared (Figure 4). 
Morphological changes were observed as early as 5 hours after the initiation ofB106 
treatment; some cells started to round up and floating cells were observed. By 24 hours of 
treatment, the majority of cells were detached or detaching from the surface of the cell 
culture plate. In contrast, rottlerin treatment did not dramatically affect the appearance of 
the cells even after 24 hours of treatment. Few floating cells were observed with rottlerin 
treatment, although the number of cells on the cell culture plate was fewer than that of 
cells treated with vehicle (DMSO) or B154, a negative control compound for PKC() 
inhibition. B 154 treatment did not change the cell morphology at any treatment time. 
Inhibition of PKC() activity induces cell growth inhibition in melanoma cell lines 
with NRAS mutations 
To investigate the effect of PKC() inhibition on tumor cell growth, I began by 
assessing survival of melanoma cells in the presence ofrottlerin or B106. In order to 
ensure the consistency among different cell lines and exclude the possibility of cell line-
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specific effects, multiple melanoma cell lines with NRAS mutations were tested: SBcl2, 
FM6, WM1366, WM1361A, WM852, FM28 and SKMEL2. The presence of genomic 
mutations in the NRAS gene was confirmed by sequencing analysis (Table 2). Cells were 
treated with rottlerin (2 or 5~M) or B106 (0.1, 0.2 or 0.5~M) and the quantity ofviable 
cells was measured at 24, 48 and 72 hours after treatment by a MTS assay (Figure 5). A 
MTS assay determines the mass of viable cells by the amount of MTS metabolite 
generated, as measured by the amount of 490nm absorbance, and this is directly 
proportional to the number of living cells in culture. Rottlerin consistently inhibited 
proliferation of all cell lines at 5~M and intermediate inhibitory effects were observed at 
2~M. The new PKCo inhibitor B 106 effectively inhibited growth of all cell lines tested at 
0.5~M, or 0.2~M in some cell lines, which is at least 10 times lower than the 
concentration of rottlerin required to exert the same degree of effect. B 154 treatment at 
2~M produced a proliferation curve similar to vehicle (DMSO) treatment in all cell lines, 
indicating cell growth inhibition induced by B 106 indeed resulted from the inhibition of 
PKCo activity. These assays demonstrated the greater potency ofB106 on tumor cell 
growth inhibition in comparison to rottlerin, with activity at nano molar concentrations. 
Subsequently, a clonogenic colony assay was performed in SBcl2 cells to test the 
kinetics of irreversible actions of PKCo inhibitors on the growth and proliferative 
characteristics of the cells. In contrast to a MTS assay which highlights the temporary 
survival ability of cells under drug treatment, a clonogenic assay illustrates more relevant 
clinical benefit. In the clinical setting, patients receive treatment for a certain amount of 
time, but anti-cancer effect of a drug is expected to sustain after the treatment is 
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terminated. In this assay, cells were treated with rottlerin or B106 for 12, 24 and 48 hours 
and then cells were replated in normal medium without drugs (washout). This assay 
assesses the timeframe required for the compounds to inflict irreversible damage to cells 
by measuring the difference in colony-forming ability of cultures grown under vehicle 
control and inhibitor treatment. Both rottlerin and B 1 06 treatment significantly decreased 
the number of colonies formed in SBc12 cells after as short as 12 hours of treatment, and 
approximately 40-fold reduction in the number of colonies was observed with 48 hours of 
drug treatment (Figure 6). This experiment demonstrated an irreversible cytotoxic effect 
of PKC8 inhibitors on tumor cell growth. 
As kinase inhibitors inevitably generate off-target effects, the effect ofPKC8-
selective inhibition on cell growth was confirmed by knocking down protein expression 
ofPKC8 using siRNA in multiple melanoma cell lines with NRAS mutations (Figure 7). 
Cells were transfected with siRNA targeting PKC8 or scrambled control siRNA at 50 or 
5nM depending on the cell line-specific optimal transfection conditions, and MTS assays 
were conducted on each day starting 3 or 4 days after siRNA transfection to measure the 
number of viable cells. Treatment with rottlerin or transfection reagent alone (without 
siRNA) served as a positive control of cell growth inhibition and a vehicle control, 
respectively. Downregulation ofPKC8, confirmed by immunoblotting, significantly 
inhibited proliferation of melanoma cells with NRAS mutation, particularly SBcl2, FM28 
and FM6. Although transfection with scrambled control siRNA produced slight 
cytotoxicity in some cell lines, the resulting proliferation curve did not greatly differ from 
that of vehicle control in these cell lines. Interestingly, the degree of protein knockdown, 
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quantified by densitometric analyses, did not appear to be the sole factor in determining 
the degree of growth inhibitory effect by siRNA transfection, as they were not correlated 
throughout cell lines. It is possible that some cell lines are more susceptible to cell growth 
inhibition resulting from PKC() downregulation, regardless the degree of knockdown. 
These assays verified that cell growth inhibition can be induced by selective 
downregulation of PKC() in melanoma cells with NRAS mutations, as was observed with 
the inhibition of PKC() activity by chemical compounds. 
Collectively, these experiments supported PKC() as a potential therapeutic target 
in melanoma with NRAS mutation, a subtype which is not susceptible to the currently-
available targeted therapies in melanoma. The new PKC() inhibitor B 106 demonstrated 
great potency for effective cancer cell growth inhibition, active at nano molar 
concentrations, and may serve as a lead compound for in vivo application in melanoma. 
Inhibition of PKC() activity triggers caspase-dependent apoptosis 
Next, I sought to determine how PKC() inhibition results in suppression of tumor 
cell growth in melanoma. Induction of apoptosis is one of the most desirable mechanisms 
for chemotherapeutic action since, theoretically, it selectively kills cells in which an 
apoptotic signal is introduced without adversely affecting surrounding cells and hence 
creates fewer chances to induce inflammation or tissue scarring (61). Apoptosis, which 
can be initiated by various stimuli, intrinsic or extrinsic inducers, is mediated in many 
cases by a proteolytic cascade of caspases, a family of cysteine proteases (62). There are 
two subtypes of caspases: initiator caspases and effector caspases. Activated by early 
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apoptotic events, initiator caspases (e.g. caspase-8, caspase-9) proteolytically activate 
effector procaspases (e.g. caspase-3, caspase-7). Activated caspase 3 and caspase 7, the 
ultimate executioners of apoptosis, trigger proteolytic cleavage of crucial key apoptotic 
proteins, which in tum leads to the late apoptotic events, including DNA fragmentation 
(62). To explore the possible involvement of apoptosis in the cell growth inhibition 
induced by PKC() inhibition, the activity of caspase 3 and 7 was assessed in cells treated 
with PKC() inhibitors. Figure 8 demonstrated that 24 hours of treatment of SBcl2 cells 
with rottlerin (211M) or B106 (0.2 and 0.51-!M) significantly increased the activity of 
caspase 3/7 compared to vehicle (DMSO) treatment. The effect ofB106 on caspase 3/7 
activation was more extensive than that ofrottlerin: 10-fold increase at 0.2!-!M and 12.5-
fold increase at 0.51-!M ofB106 treatment, in contrast to 5-fold increase by rottlerin 
treatment at 5!-!M. The negative control compound Bl54 did not induce the activity of 
caspase 3/7. This experiment indicated the involvement of caspase 3/7 -mediated 
apoptosis in response to PKC() inhibition. This was further investigated by examining 
subsequent event characteristic of apoptosis, in the following experiment. In Figure 9, the 
degree of DNA fragmentation, a hallmark of later events in the sequence of the apoptotic 
process, in the presence or absence of PKC() inhibitors was assessed by means of a flow 
cytometric analysis using propidium iodine staining of DNA. This assay provides 
information on cellular DNA content in the cell population by dividing the population 
based on DNA content detected by the amount of propidium iodide incorporated in DNA. 
The proportion of cells containing a DNA content of less than 2n, that is, fragmented 
DNA, categorized into the "sub-G 1" population and considered to be undergoing the late 
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apoptotic phase DNA fragmentation, was significantly higher after treatment with 
rottlerin at SflM and even higher after treatment with B106 at 0.5f!M, whereas B154, a 
negative control compound for B106 with little PKC8 inhibitory activity, produced the 
same fraction of fragmented DNA as vehicle control (DMSO), suggesting the effect of 
B106 on DNA fragmentation was caused by inhibiting PKC8 activity (Figure 9). To 
determine whether activation of caspases by these PKC8-inhibitory compounds was 
necessary for the observed apoptosis, the pan-caspase inhibitor Z-V AD-FMK 
(carbobenzoxy-valyl-alanyl-aspartyl-[Omethyl]-fluoromethylketone) was employed. Z-
V AD-FMK irreversibly binds to the catalytic site of caspase proteases and prevents 
caspases from being cleaved and activated. Pre-treatment of cells with Z-V AD-FMK 
(50f!M) prevented B106-induced caspase 3 cleavage in a preliminary immunoblot 
analysis (data not shown). B 1 06-induced DNA fragmentation was significantly abrogated 
when Z-VAD-FMK (lOOJ.!M) was used in SBcl2 cells (Figure 9). Treatment of Z-VAD-
FMK alone produced only a similar fraction of sub-G 1 cells as did vehicle or B 154 
treatment. Taken together, these data suggest that PKC8-inhibition attenuates tumor cell 
growth by inducing caspase-dependent apoptosis in NRAS-mutated melanoma cells. 
B106 in a mouse tumor xenograft model 
Based on the potent anti-tumor activity ofB106 in the melanoma cell culture 
systems, I proceeded to test the efficacy of B 106 in vivo in a mouse xenograft tumor 
model. Tumor blocks of SBcl2 cells were implanted into 12 mice and dosing was started 
8 days after tumor implantation; 6 mice received B 106 intraperitoneally at 40 mg/kg and 
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the other 6 mice were given DMSO, the vehicle solvent ofB106, daily for 12 consecutive 
days. Tumor size was measured daily and tumor growth rate was calculated. Treatment of 
B106 did not produce any difference in tumor growth compared to the DMSO-treated 
group (Figure 10). There are, however, two concerns remaining at this point regarding 
pharmacokinetics ofB106. First, it is unclear whether the drug entered into the systemic 
circulation and delivered to the local areas, as B 106 is extremely hydrophobic and could 
not be diluted with hydrophilic solvent. Secondary, there is no information regarding how 
fast the drug is metabolized at this time. A new generation of compounds with 
hydrophilic modification of the B 106 structure is currently being synthesized (Figure 
11). When any of these compounds is revealed to be as potent as B106 in the cell culture 
system, its in vivo efficacy and pharmacokinetics will be tested. 
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Figure 3: Chemical structures of PKCo inhibitors. (A) Rottlerin, (B) BJE6-1 06 
[referred as B106], (C) BJE6-154 [referred as B154]. BJE6 compounds were designed 
based on the structures ofpan-PKC inhibitor (for potency) and rottlerin (for isozyme 
specificity). 
Compounds PKCo PKCa PKCo/PKCa In vitro In vivo 
ICso ICso Selectivity Ras-specific Ras-specific 
Cytotoxicity Cytotoxicity 
Rottlerin 3f.!M 75f.!M 28-fold 3J1M Yes 
B106 0.05 f.!M 50f.!M 1000-fold 0.5 f.!M Not active* 
B154 >25f.!M >100 f.!M - - No 
Table 1: Comparison ofPKCo inhibitors. In vitro kinase assays demonstrated that 
B 1 06 is more potent as a PKCo inhibitor and more selective against PKCo over PKCa 
than rottlerin. *:not yet optimized for drug-like properties, so in vitro activity represents 
a minimum of the potential activity of a more hydrophilic derivative. 
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Figure 4: Comparison of morphological changes induced by PKCo inhibitor 
treatment in SBc12 cells. Cells were treated with rottlerin (5~M) or B106 (0.5~M) for 
the indicated times and microphotographs were taken at a lower (left) and a higher 
magnification (right). DMSO and B154 (0.5~M) served as a vehicle control and a 
negative compound control, respectively. Cell morphological changes and induction of 
floating (dead) cells started as early as 5 hours of B 106 treatment. In contrast, rottlerin 
treatment did not affect the appearance of cells within 24 hours, although the number of 
the cells per well remained lower in rottlerin-treated cells than that in cells treated with 
vehicle or B154. 
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Cell line Genomic Amino acid Allele 
mutation mutation 
SBcl2 C181A Q61K Homozygous 
FM28 C181A Q61K Homozygous 
FM6 C181A Q61K Heterozygous 
WM852 A182G Q61R Homozygous 
SKMEL2 A182G Q61R Heterozygous 
WM-1361A A182G Q61R Heterozygous 
WM-1366 A182T Q61L Heterozygous 
Table 2: NRAS Q61 mutations of cell lines used in the project. 
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Figure 5: Effect of rottlerin and B106 on cell survival in melanoma cell lines with 
NRAS mutation. SBcl2, SKMEL2 FM6, WM1361A and WM1366 cells were treated 
with rottlerin (2 or 5J..LM) or B106 (0.1, 0.2 or 0.5J..LM) for 24,48 or 72 hours. MTS assays 
were performed at each time point, with the amount of 490nm absorbance being 
proportional to the number of viable cells. DMSO and Bl54 (2J..LM) served as a vehicle 
control and a negative compound control, respectively. Each point represents the average 
of triplicates and error bars indicate the standard deviations of triplicates. P values (*) 
were calculated between DMSO (vehicle control) and rottlerin 5J..LM, or DMSO and B106 
0.5J..LM in each cell line at 72 hours (p < 0.0002). The experiment was repeated at least 
twice in each cell lines. 
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Figure 6: Irreversible effect of rottlerin and B106 on cell growth (clonogenic colony 
assay) in SBcl2 cells. Cells were treated with rottlerin or B106 at 5jlM for 0, 12, 24 or 48 
hours. After these treatment time, the same number of viable cells from each treatment 
was replated at the low cell density and cells cultured in normal medium for 8 days, by 
which time colony formation was distinctly observed. Cell colonies were stained with 
ethidium bromide for visualization and counting. Each point represents the average of 
triplicates and error bars indicate the standard deviations of triplicates. P values: ** 
p<O.Ol , * p<O.OOl compared to time Oh. The experiment was repeated twice. 
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Figure 7: Effect ofPKC() knockdown on cell survival in melanoma cell lines with 
NRAS mutation. siRNA targeting PKCo ("siPKCo") or scrambled siRNA ("siControl") 
were transfected into SBcl2 and FM28 (50nM), and to FM6 and WM1366 (5nM). 
Rottlerin (5).tM) served as a positive control of cell growth inhibition and "vehicle 
control" or "vehicle" indicates treatment with transfection reagent alone as another 
negative control. MTS assays were performed at the indicated days after siRNA 
transfection to measure the amount of 490nm absorbance being proportional to the 
number of viable cells. Each point represents the average of triplicates and error bars 
indicate the standard deviations oftriplicates. P values(*) were calculated between 
vehicle control and siPKCo on the last MTS-assay-day (p < 0.006). Downregulation of 
PKCo protein on the first assay-day was assessed by immunoblotting. The relative band 
intensity of PKCo was indicated below the image (normalized to loading controls, ~-actin 
or GAPDH). The experiment was repeated at least twice in each cell line. 
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Figure 8: Activation of caspase 317 induced by PKC() inhibitors in SBcl2 cells. Cells 
were treated with rottlerin (2 or 5f.LM) or B106 (0.2 or 0.5f.lM) for 6, 12 or 24 hours and 
caspase 3/7 activity was measured by luminescense at each time point. DMSO and B 154 
(1 f.LM) served as a vehicle control and a negative control for PKC8 inhibition, 
respectively. The assay reagent contains a luminogenic substrate bound to a caspase 3/7 
target peptide sequence. The amount of luminescence is proportional to the amount of 
activated caspase 3/7, which releases the luciferase substrate, making it available for 
reaction by cleaving it at the target sequence. Values of each treatment and time point 
were normalized to that of vehicle-treated sample at 6 hours. Error bars indicate the 
standard deviations of triplicates. P values: ** p < 0.003, * p < 0.0002. The experiment 
was repeated twice. 
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Figure 9: DNA fragmentation induced by PKCB inhibitors in SBcl2 cells. Cells were 
treated with rottlerin (5!-LM), B106 (0.5!-LM) alone, or B106 (0.5!-LM) plus the pan-caspase 
inhibitor Z-V AD-FMK (100!-LM) together for 24 hours. The proportion of sub-G 1 
population was measured by flow cytometric analysis using propidium-iodide staining of 
DNA. DMSO and B154 (0.5!-LM) served as a vehicle control and a negative control for 
PKC() inhibition, respectively. Values represent the average of duplicates and error bars 
indicate the standard deviations of duplicates. Cells in the sub-G 1 population have 
fragmented DNA, which is a hallmark event of the late apoptotic process. Z-V AD-FMK 
(carbobenzoxy-valyl-alanyl-aspartyl-[Omethyl]- fluoromethylketone) irreversibly binds 
to the catalytic site of caspase proteases and prevents caspases from being cleaved and 
activated. Preliminary immunoblot analysis verified the effect of Z-V AD-FMK at 50!-LM 
on prevention of caspase 3 cleavage (data not shown). P values: ** p < 0.04, * p < 0.004. 
The experiment was repeated three times. 
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Figure 10: Mouse xenograft model with B106 daily dosing. Donor athymic nude mice 
were subcutaneously injected with 3 x 106 cells ofthe SBcl2 cell line and tumors were 
grown. The resulting tumors were harvested, dissected into small blocks (approximately 
3 mm3) and frozen for later use. For the xenograft study, tumor blocks were implanted 
subcutaneously into 12 mice (1 block I implantation) and 8 days later, when tumor 
growth was apparent, dosing was initiated. 6 mice were treated with vehicle (DMSO) 
administered intraperitoneally and the other 6 mice were treated with B 106 ( 40 mg/kg) 
daily for 12 consecutive days. Tumor size was measured daily using a caliper and tumor 
growth rate was calculated. Each point represents the average tumor growth rate of 6 
mice and error bars indicate the standard deviations. 
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Figure 11: Proposed modifications ofB106 to explore Structure-Activity 
Relationships (SAR) and improve pharmaceutical properties. Rl and R2, which are 
hydroxyl groups in rottlerin and are hydrogen atoms in B 106, will be sequentially 
substituted with OH groups, which should improve water solubility. In addition, we plan 
to perform an isosteric replacement of the aromatic CH groups (X and Z) with basic 
nitrogen atoms which will be protonated at physiological pH providing for additional 
water solubility and perhaps improved potency. 
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1-3. Summary 
Based on the previous studies that reported its role as essential for survival in RAS-
mutated cancer cells while being non-essential for survival of normal cells, PKC8 
presented potential as a therapeutic target in melanoma with NRAS mutation. Both of the 
PKC8 inhibitors rottlerin and B 106, which was developed in our lab, inhibited cell 
growth in melanoma cell lines carrying NRAS mutations, and the specificity of PKC8 
inhibition in the cytotoxic effect was verified by specific downregulation using siRNA 
targeting PKC8. Promisingly, B106 effectively exerted a cell growth inhibitory effect at 
nanomolar concentrations throughout the cell lines tested, in comparison to rottlerin 
which required 10 times higher concentration to induce the same degree of effect. The 
cell growth inhibition in these cells caused by PKC8 inhibition is likely due to caspase-
dependent apoptosis. The in vivo efficacy of B 106 is still undetermined at this time. 
When more soluble analogs of B 106 are available and their in vitro potency is verified, 
their in vivo efficacy as well as pharmacokinetics will be investigated. 
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Chapter 2: Molecular mechanism by which PKC() inhibition causes 
cytotoxicity in melanoma: PKC<> inhibition causes caspase-dependent 
apoptosis via the JNKIH2AX pathway 
2-1. Introduction 
Stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) is activated 
in response to cellular stresses, including genotoxic stresses (e.g., ionizing radiation (IR), 
ultraviolet radiation (UV)), chemotherapeutic agents, or reactive oxygen species (ROS) 
and is involved in a variety of cellular activities, such as cell proliferation, differentiation, 
inflammatory response, apoptosis, motility, metabolism and DNA repair (63-66). 
The JNK pathway comprises one of the three major MAPK pathways. The JNK 
family is on the MAPK tier and consists ofthree isozymes: JNKl , JNK2 and JNK3. 
JNKl and JNK2 are ubiquitously expressed while JNK3 is restricted to brain, heart and 
testis (63). Alternative splicing yields multiple splicing variants of all three isozymes: 
each of JNKl and 2 genes contributes both a short form ( 46kDa) and a long form 
(54kDa) and a minor 52kDa form is believed to derive mostly to JNK3 (63 , 67). Upon 
activation of the JNK pathway, both the 46kDa and 54kDa forms become phosphorylated 
at Thr183/Tyrl85 by two upstream MAPKKs, SEK1 /MKK4 and MKK7. MKK4 appears 
to preferentially phosphorylate Tyr185 and MKK7 favors Thr183 (68). While MKK7 is a 
INK-selective MAPKK, MKK4 is capable of activating both JNK and the other MAPK, 
p38 (69). The most well-studied of the downstream substrates of JNK are components of 
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activator protein-1 (AP-1 ), a transcription factor that binds to TRE/ AP-1 elements and 
activates transcription. The AP-1-associated proteins activated by JNK include c-Jun, 
JunD, and activating transcription factor 2 (ATF2) (68) (Figure 12). Other substrates of 
JNK include a wide range of proteins: Elk1 , c-Myc, p53, MLIQ, NFATc2, TIF-1A, 
histone H3, insulin receptor substrate 1 or JIP1 (68). In response to apoptotic signals, 
JNK activates the pro-apoptotic Bcl-2 family proteins Bax and Bad, possibly in part 
through regulating BH3-only members of the Bcl-2 family including Bim, Bid or Bif, 14-
3-3 or FOXO transcription factor (66) (Figure 12). 
Recently, H2AX, a histone H2AX variant, was found to be phosphorylated by 
JNK (70). Phospho-H2AX is known to localize to DNA double-strand breaks (DSBs) on 
replication foci as part of a repair complex, and is used as an indicator ofDSBs in studies 
of DNA damage response. While previous studies suggested that H2AX phosphorylation 
is the consequence of a series of apoptotic events (71 ), a recent study proposed that JNK-
mediated H2AX phosphorylation at Ser139 may instead be actively involved in the 
apoptotic process through induction ofDNA fragmentation in UV-damaged cells (70) 
(Figure 12). Subsequently, another report demonstrated that the pan-nuclear distribution 
of phosphorylated H2AX is a pre-apoptotic signal associated with ATM- and JNK-
dependent apoptosis during S-phase, in contrast to replication foci-specific localization at 
DSBs (72). Interestingly, a series of recent studies supported this model of an active 
apoptotic role for H2AX, including involvement in apoptosis induced by radiation and 
chemotherapeutic agents such as enzastaurin and imatinib mesylate (73-76). 
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PKC8-mediated regulation of JNK pathway signaling was reported by several 
groups, especially in association with the pro-apoptotic function of PKC8 (18, 22-24, 27). 
On the other hand, downregulation ofPKC8 using RNAi initiated JNK-mediated 
apoptosis in prostate cancer cells with Ras activation, suggesting that the anti-apoptotic 
actions ofPKC8 also possibly involve activation of the JNK pathway (47). 
In this chapter, the molecular mechanism ofPKC8 inhibition which leads to 
caspase-dependent apoptosis in melanoma cell lines carrying NRAS mutations is 
examined. Inhibition of PKC8 by B 1 06, or by siRNA, induced the stress-responsive JNK 
pathway (MKK4/JNK/H2AX) and phospho-H2AX is shown to be essential in B106-
induced apoptosis. 
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Figure 12: JNK/H2AX pathway. The JNK pathway comprises one of the three major 
MAPK pathways. Upstream of JNK, MKK4 is phosphorylated at S257 and MKK7 at 
S271/T275 by MAPKKK resulting in their activation. MKK7 is selective for JNK, while 
MKK4 phosphorylates JNK as well as p38. Activated JNK exerts a wide range of 
downstream responses, including activation of transcription factors or pro-apoptotic 
modulators. Phospho-H2AX is primarily known for its role in DNA repair and 
localization to DNA double-strand breaks (DSBs) on replication foci , and is used as an 
indicator ofDSBs. A series of recent reports proposed an active role ofphospho-H2AX 
in apoptosis by induction of DNA fragmentation. 
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2-2. Results 
PKCo inhibition induces the stress-responsive JNK pathway 
In order to identify which intracellular signaling pathway PKC() inhibition 
employs to induce cytotoxicity, the activation status of reported downstream targets of 
PKC() was examined after PKC() inhibition, including MAPKs (ERK, p38 and JNK), 
AKT, NFKB pathway, CDK inhibitors, p53, lAPs, GSK3~ or c-Abl by immunoblotting of 
individual proteins. A phospho-protein focused antibody array was also used. These 
studies revealed that B106 treatment induced phosphorylation of JNKl/2 most strongly 
after two hours of exposure, with phosphorylation diminishing subsequently, in SBcl2 
cells (Figure 13). In contrast, activation of the other MAPKs p38 and ERK was not 
consistently observed (Figure 13). Slight increases in phosphorylation of AKT were 
occasionally seen after rottlerin treatment (Figure 13). 
The upstream and downstream effectors of the JNK pathway were next examined. 
The upstream MAPKK, MKK4, was activated by B106 but MKK7 was not. This was 
somewhat unexpected, as MKK7 activation was anticipated because of its more selective 
function to activate JNK relative to p38 (Figure 14). The activation ofthe well-described 
JNK substrate, c-Jun, was also observed, confmning the activation of the JNK pathway 
by B106 treatment (Figure 14). Furthermore, Figure 14 demonstrated the activation of 
H2AX at later time points in response to B106 treatment. B106 consistently induces 
H2AX phosphorylation as early as 10 hours to 24 hours (times later than 24 hours were 
not studied because significant cytotoxicity is occurring after this time). Phosphorylation 
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ofH2AX was occasionally, but not consistently, observed after rottlerin treatment, in the 
absence of activation of MKK4/JNK, implying the potential existence of another 
mechanism that causes H2AX phosphorylation other than the JNK pathway; possibly, 
mediation by other kinases or secondary consequence of DNA fragmentation in the 
course of the apoptotic event initiated by rottlerin treatment. To ensure that activation of 
JNK pathway by B106 is not a cell-type-specific response, the pathway effectors were 
examined in another NRAS mutant melanoma cell line WM1366. Activation ofMKK4, 
JNK and H2AX was confirmed in these cells (Figure 15) as well as other NRAS-mutated 
melanoma cell lines, WM852 and FM28 (data not shown). 
Collectively, these data suggest that B106 treatment activates MKK4, directly or 
indirectly, which turns into the activation of JNKl/2 and eventually H2AX. 
Selective downregulation of PKCo verifies the effect of PKCo inhibitors on 
JNKIH2AX activation 
As discussed in Chapter 1, the target specificity of PKC8 inhibitors resulting 
JNK-pathway activation needed to be confirmed by more selective downregulation of 
PKC8 using siRNA, especially because rottlerin and B 106 produced differences in the 
activation of the JNK pathway. Consistent with the observations following B106 
treatment described above, selective downregulation of PKC8 by PKCo-specific siRNA 
transfection induced phosphorylation of JNKI /2 at 24 hours (when effects of siRNA on 
PKC8 levels are first observed), in contrast to transfection with negative control 
scrambled siRNA. No difference between PKCo and negative control siRNA 
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transfectants was observed on the phosphorylation levels ofERK or p38 (Figure 16A). 
Phosphorylation of H2AX was observed at 72 hours after PKC8 siRNA transfection 
compared to the cells transfected with negative control siRNA. This was consistent with 
my observation ofH2AX phosphorylation subsequent to the initiation of the MKK4/JNK 
cascade activation seen with PKC8 inhibitor treatment (Figure 16B). These results 
verified that the selective inhibition ofPKC8 induces activation of the JNK/H2AX 
signaling in NRAS mutant melanoma cells, and supported my hypothesis that the effect 
of B 106 on JNK/H2AX pathway is likely to be causally related to PKC8 inhibition. 
B106-induced phosphorylation of H2AX is mediated via JNK 
Because JNK affects diverse downstream effectors, I then investigated whether 
JNK activation caused by PKC8 inhibition is directly linked to B106-induced H2AX 
activation. Cells were transfected with either negative control siRNA or JNKl/2 siRNA 
for 72 hours and then treated with vehicle or B 106 for another 24 hours. Knockdown of 
JNKl/2 itself slightly reduced basal phospho-H2AX expression, indicating that basal 
phosphorylation of H2AX is indeed regulated by JNK (Lane 2, Figure 17). B 106 
treatment robustly induced phosphorylation of H2AX (pH2AX) in control siRNA-treated 
cells (Lane 3, Figure 17) as expected; in comparison, prior downregulation of JNKl/2 
protein greatly suppressed B 1 06-induced H2AX phosphorylation (Lane 4, Figure 17). 
This experiment confirmed that JNK lies upstream of H2AX, and H2AX is not activated 
in the absence of JNK in response to PKC8 inhibition, supporting the model in which 
inhibition of PKC8 by B 106 causes JNK/H2AX pathway signaling. 
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Caspase-dependent apoptosis initiated by B106 treatment is mediated via 
JNKIH2AX pathway 
Although phosphorylation of H2AX has been primarily considered to be a 
consequence of/response to DSBs in the DNA damage response, a recent study reported 
that phosphorylation of H2AX resulting from JNK activation actively mediates the 
induction of apoptosis (70) (Figure 12). This report, together with the above observations 
ofB106-induced activation of the JNK/H2AX pathway and caspase-dependent apoptosis 
(Chapter 1), led me to hypothesize that inhibition ofPKCo activity by B106 causes 
caspase-dependent apoptosis through activation of the JNK/H2AX pathway. 
Accordingly, the effect of inhibition of the JNK pathway during B106 treatment was 
explored. In Figure 18, cells were transfected with siRNA specific for JNK1 or 2 alone, 
or co-transfected with JNK1 and 2 siRNA together for 72 hours and then treated with 
B106 for 6, 12 or 24 hours, followed by measurement of caspase activity. Analysis at 24 
hours after B 106 treatment showed that knockdown of JNK2, and co-knockdown of 
JNK1 and 2, mitigated B 1 06-induced caspase 3/7 activation in rough proportion to the 
knockdown efficiency of JNK1/2 proteins, as confirmed by immunoblotting (Figure18). 
Similarly, as expected from the observed causal link from JNK activation to H2AX 
phosphorylation after PKCo inhibition (Figure 17), downregulation of H2AX prior to 
B 106 treatment greatly decreased the level of caspase 3/7 activation at 24 hours after 
B106 treatment compared to the cells pre-treated with control siRNA (Figure 19). These 
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experiments suggested that JNK activation/phosphorylation of H2AX is required for the 
activation of caspases, the ultimate executers of apoptosis, during PKCcS inhibition. 
Subsequently, in order to explore the more direct link ofH2AX in the execution 
of apoptosis, PKCcS inhibition-induced DNA fragmentation, a hallmark of the late 
apoptotic process which is seen in cells destined for apoptosis, was examined in the 
presence or absence ofH2AX. Similar to the results shown in Figure 19, SBc12 cells 
were transfected with either negative control siRNA or siRNA targeting H2AX for 72 
hours, and then subjected to PKCcS inhibition by B 106 treatment for the next 24 hours. 
DNA fragmentation was assessed by flow cytometric analysis using propidium iodide 
staining of DNA. PKCcS inhibition by B106 treatment increased DNA fragmentation 8.5-
fold in the cells transfected with negative control siRNA (Figure 20). In contrast, PKCcS 
inhibition by B 106 treatment failed to induce DNA fragmentation in the absence of 
H2AX induced by transfection of siRNA against H2AX (Figure 20). B 1 06-induced DNA 
fragmentation in the cells with H2AX downregulation was significantly reduced 
compared to that in the cells with H2AX expression, indicating that H2AX is necessary 
for B106-induced apoptosis (Figure 20). Collectively, these results suggest that 
inhibition of PKCcS by B 106 treatment triggers caspase-dependent apoptosis through 
activation of the JNK-H2AX stress-responsive signaling pathway. 
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Figure 13: JNK activation by B106 in SBcl2 cells. Cells were treated with rottlerin 
(5!-LM) or B106 (111M) for the indicated times. B154 (111M) served as a negative 
compound control for B 106. Protein lysates were subjected to immunoblotting for 
phosphorylation or total expression level of MAP kinase proteins. Note: each of JNK.l 
and 2 genes contributes both a short form (46kDa: lower arrow) and a long form (54kDa: 
upper arrow) of the protein, as a result of differential splicing. The experiment was 
repeated at least three times. 
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Figure 14: Activation of upstream and downstream components of the JNK 
pathway by B106 in SBc12 cells. Cells were treated with rottlerin (5J.!M) or B106 (lJ.LM) 
for the indicated times. B 154 (1 J.!M) served as a negative compound control for B 106. 
Protein lysates were subjected to immunoblotting for phosphorylation or total expression 
levels of proteins. Activation ofMKK4 (activator of JNK), H2AX and c-Jun (target of 
JNK) was observed; however, activation ofMKK7, the alternate MAPKK for JNK, could 
not be detected. Levels of a-tubulin served as a loading control. The experiment was 
repeated at least three times. 
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Figure 15: Activation of upstream and downstream components of the JNK 
pathway by B106 in WM1366 cells. In order to verify that the preceding observation of 
the activation ofthe JNK pathway in SBcl2 cells is not specific to the cell type, WM1366 
cells (NRAS mutant melanoma cell line) were treated with rottlerin ( 5 J.!M) or B 1 06 
(lJ.!M) for the indicated times. B154 (lJ.!M) served as a negative control for PKC8 
inhibition. Protein lysates were subjected to immunoblotting for phosphorylation or total 
expression levels of proteins. Levels of a-tubulin served as a loading control. The 
experiment was repeated at least two times. 
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Figure 16: Knockdown of PKCo induces phosphorylation of JNK and H2AX in 
SBc12 cells. (A) Cells were transfected with scrambled negative control ("siControl") or 
PKC8 siRNA ("siPKCo") at 5nM for the indicated times. B 106 treatment (1 ~M) serves 
as a positive control of JNK activation. Protein lysates were subjected to immunoblotting 
for phosphorylation and total expression levels of MAPK proteins. The experiment was 
repeated at least two times. (B) Cells were transfected with scrambled negative control 
("siControl") or PKCo siRNA ("siPKCo") at 50nM for the indicated times. B 106 
treatment at 0.5~M served as a positive control ofH2AX activation. Protein lysates were 
subjected to immunoblotting for phosphorylation and total expression levels ofH2AX 
protein. Levels of GAPDH served as a loading control. The experiment was repeated 
three times. 
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Figure 17: Prior downregulation of JNK prevents B106-induced H2AX activation in 
SBcl2 cells. SBcl2 cells were co-transfected with siRNA against JNK.l and JNK2 (5nM 
each) or scramble siRNA (lOnM) for 72 hours and subsequently with B106 (0.5)lM) or 
vehicle for 10 hours. Protein lysates were subjected to immunoblotting for 
phosphorylation and total expression levels of proteins. The relative band intensity of 
phospho-H2AX was indicated below the image (normalized to total H2A). Levels of 
GAPDH served as a loading control. The experiment was performed once. 
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Figure 18: Activation of caspase 317 is mitigated by knockdown of JNK prior to 
B106 treatment in SBcl2 cells. (Top) SBcl2 cells were transfected with negative control 
siRNA (1 OnM), siRNA against JNK.l or JNK2 alone (5nM), or the combination of JNK.l 
and JNK2 (5nM each) for 72 hours, and subsequently treated with B106 (0.5!lM) or 
vehicle for 6, 12 and 24 hours. Activity of caspase 3/7 was measured by luminescence at 
each time point. The average values of triplicates were normalized to that of the vehicle-
treated sample at 6 hours between the pairs of the same siRNA with or without B106 
treatment. Error bars indicate the standard deviations of triplicates. P values: * p < 0.005. 
(Bottom) Downregulation of JNKl /2 proteins were confirmed by immunoblotting. Cells 
were lysed after 72 hours ofsiRNA transfection. Each ofthe two bands detected in 
immunoblotting with JNK.l /2 antibodies represent assembly of different splicing variants 
from both JNKI and 2 isoforms. Levels of GAPDH served as a loading control. The 
experiment was repeated twice. 
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Figure 19: Activation of caspase 3/7 is mitigated by knockdown ofH2AX prior to 
B106 treatment in SBcl2 cells. (Top) Cells were transfected with negative control 
siRNA (5nM) or siRNA against H2AX (5nM) for 72 hours, and subsequently treated 
with B106 (0.5J..LM) or vehicle for 6, 12 and 24 hours. Activity of caspase 3/7 was 
measured by luminescence at each time point. The average values of triplicates were 
normalized to that of the vehicle-treated sample at 6 hours between the pairs of the same 
siRNA with or without B 1 06 treatment. Error bars indicate the standard deviations of 
triplicates. P value:* p < 0.002. (Bottom) Downregulation ofH2AX mRNA was 
confirmed by real-time PCR. mRNA was collected 72 hours after siRNA transfection 
(5nM), from which eDNA was synthesized. Relative amount ofH2AX mRNA was 
calculated by normalizing Ct value of H2AX to that of ~-actin (internal control) obtained 
from real-time PCR. The experiment was repeated twice. 
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Figure 20: Induction of DNA fragmentation is mitigated by knockdown of H2AX 
prior to B106 treatment in SBcl2 cells. (Top) Cells were transfected with negative 
control siRNA (5nM) or siRNA against H2AX (5nM) for 72 hours, and subsequently 
treated with B 106 (0.5 J.!M) or vehicle for 24 hours. The proportion of sub-G 1 population 
was measured by flow cytometric analysis using propidium-iodine staining. The average 
values of duplicate were normalized to that of the vehicle-treated sample between the 
pairs of the same siRNA with or without B106 treatment. Error bars indicate the standard 
deviations of duplicates. P value: * p < 0.0004. (Bottom) Downregulation of H2AX 
mRNA was confirmed by real time PCR. mRNA was collected 72 hours after siRNA 
transfection (5nM), from which eDNA was synthesized. Relative amount ofH2AX 
mRNA was calculated by normalizing the Ct value ofH2AX to that of ~-actin (internal 
control) obtained from real-time PCR. The experiment was repeated three times. 
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2-3. Summary 
To better understand the molecular mechanism of action of the PKC5 inhibitor 
B 106 as well as the effect of PKC5 inhibition itself, the signaling pathway that PKC5 
inhibition employs to initiate caspase-dependent apoptosis was sought in this chapter. 
Among the reported downstream targets of PKC5, B 106 treatment and PKC5 knockdown 
was shown to induce activation of the JNK cascade, a stress responsive MAPK pathway. 
A series of focused analyses of the signaling pathway identified that the 
MKK4/JNK/H2AX cascade is induced by treatment with B106 in four melanoma cell 
lines with NRAS mutations. Selective downregulation of PKC5 using siRNA verified the 
activation of JNK and H2AX subsequent to PKC5 inhibition. JNK was essential for 
B106-induced H2AX activation, and the phosphorylation ofH2AX by B106 treatment 
was abrogated in the absence of JNK expression. Consistent with a necessary role for 
JNK and H2AX in this apoptotic signaling cascade, caspase activation was suppressed 
when either JNK or H2AX was downregulated prior to B 1 06 exposure, and more 
importantly, DNA fragmentation initiated by B106 treatment was prevented by prior 
knockdown of H2AX. These results suggest that PKC5 inhibition, either by B 1 06 
treatment or by siRNA transfection, initiates caspase-dependent apoptosis through 
activation of the stress-responsive kinase cascade MKK4-JNK-H2AX. 
Phosphorylation of H2AX has long been identified as a cellular response to DNA 
double strand breaks; however, a series of recent reports proposed an active role for 
H2AX phosphorylation in apoptosis. My finding of H2AX as an apoptotic mediator in 
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apoptosis induced by PKC8 inhibition in cells with aberrant Ras signaling not only 
supports this model but also demonstrates a necessary role for phospho-H2AX, in that the 
absence of H2AX suppresses the initiation of apoptosis. 
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Chapter 3: PKCB inhibition induces growth inhibition in B-Raf 
inhibitor-resistant melanoma cells 
3-1. Introduction 
In the search for potential therapeutics to block aberrant activation of the 
Raf/MEKIERK pathway in cancer cells, pharmacological inhibitors of Raf kinases and 
MEK kinases have been intensively pursued. Among three Raf isozymes, the discovery 
of frequent BRAF mutations in a wide range of cancers attracted attention to B-Raf as a 
druggable target (77). Theoretically, specifically targeting mutant B-Raf, the expression 
of which is confmed to cancer cells, would enable tumor-selective drug activity, while 
sparing normal cells that carry wild-type B-Raf. Most investigational drugs currently in 
clinical trials are selective for the BRAF-V600E mutant, which is particularly common in 
melanoma. The recently FDA-approved agent vemurafenib (also known as PLX4032) 
preferentially inhibits the V600E mutant form ofB-Raf over wild-type (78). Inhibition of 
ERK phosphorylation, induction of cell cycle arrest, and apoptosis induced by PLX4032 
are exclusively observed in BRAF-V600E-positive cells (78). A phase II trial in 
previously-treated melanoma patients with mutant B-Raf achieved a remarkable response 
rate of 53% and a median duration of response of 6.7 months (79). A phase III trial which 
compared the efficacy of vemurafenib to that of dacarbazine in patients with previously-
untreated BRAF-V600E-positive melanomas verified the higher response rate and 
improved rates of overall survival and progression free survival (PFS) over the standard 
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treatment group (7). Vemurafenib was approved by FDA in 2011 for the treatment of 
patients with previously untreated metastatic or unresectable melanoma with the BRAF-
V 600E mutation, with concurrent approval of a BRAF-V 600E mutation assay 
(companion diagnostic). Among the investigational drugs in this class, the most advanced 
at this time is dabrafenib, which has higher specificity against mutant B-Raf and a similar 
preclinical profile to vemurafenib (80). Encouraged by a phase II trial that confirmed a 
59% response rate to dabrafenib in melanoma, several phase III trials are currently 
ongoing. Preliminary result from a randomized monotherapy trial reported improved 
median PFS over dacarbazine treatment (80). 
While these mutant B-Raf inhibitors produce improved overall survival in the 
patients with BRAF mutations compared to standard treatment options, a major challenge 
remains: essentially all patients treated with these drugs relapse due to the development 
of drug resistance, with the median time to progression (TTP) of 7 months for 
vemurafenib and 5 months for dabrafenib (79, 80). Several models for resistance have 
been proposed: 1) reactivation of the MEK/ERK pathway, bypassing mutated BRAF 
(e.g., secondary mutation in NRAS, hyperactivation!overexpression ofC-Raf, or 
activation of another MAPKK COT); or, 2) adaptive dependency upon alternative 
pathways (hyperactivationloverexpression ofRTKs, such as PDGFRP or IGF1R, or the 
AKT pathway) (Figure 21) (8, 81-83). 
Another issue that needs to be addressed regarding B-Rafinhibitors is the 
potential risks of their use in RAS-mutant melanoma. Interestingly, B-Rafmutant-
selective inhibitors were reported to paradoxically activate the MEK-ERK pathway via 
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C-Rafin a Ras activity-dependent manner in RAS-mutant cells, leading to accelerated 
cell proliferation (84-87). Moreover, RAS mutations (predominantly HRAS) were 
detected in 60% of tumor samples taken from patients who developed secondary tumors 
(cutaneous squamous-cell carcinomas and keratoacanthomas) after treatment with B-Raf 
inhibitors (88). In this report, HRAS mutation was demonstrated to be associated with 
accelerated cell proliferation due to increased MAPK pathway activity both in vitro and 
in vivo in response to exposure to B-Raf inhibitors. Recently, acceleration of an acute 
myelogenous leukemia with mutant Ras was reported as a result of vemurafenib therapy 
for melanoma (89). While the sequence of the event between the evolution of RAS 
mutations and the development of secondary tumors is still unclear, these reports suggest 
that the mutational status of the RAS genes should be carefully monitored in patients who 
are treated with a mutant specific B-Raf inhibitor over the course of the treatment. 
Furthermore, they also highlight the urgent need to develop therapies selectively targeting 
RAS-mutated melanomas. As described in Chapter 1, targeting Ras protein themselves 
was discovered to be extremely difficult, underlining the need for alternative strategies in 
these types of melanomas, such as the synthetic lethal approach introduced in Chapter 1. 
In this chapter, the efficacy ofB106 in BRAF-mutated melanoma cell lines that 
have developed resistance to vemurafenib (called by its alternative name PLX4032 in the 
following section), the mechanism of drug resistance, and its potential relation to NRAS-
mutated cells are studied. The differential response to B106 between PLX4032-resistant 
cells and their parental cells provides an insight towards the potential clinical application 
of PKC8 inhibitors in the future. 
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Figure 21: Mechanism of action and resistance to B-Raf inhibitors. (Left) 
Mechanism of action: B-Raf inhibitors prevent transmission of the MEKJERK pathway 
specifically in tumorigenic cells carrying mutant B-Rafwhich have low Ras activity. 
(Middle) Mechanism of resistance (reactivation ofMEKIERK pathway): Secondary 
mutation in NRAS converts normal N-Ras protein that is activated only on GTP-bound 
state into oncogenic Ras protein that is constitutively activated (1 ). High Ras activity 
induces heterodimerization of mutant B-Raf with C-Raf (2) or increases dependency on 
other Raf family members (3) in accordance with hyperactivation or overexpression of C-
Raf. These events reactivate MEKJERK pathway by bypassing B-Rafinhibition by the 
inhibitors. (Right) Mechanism of resistance (activation of alternative pathways): 
constant inhibition of B-Raf increases the activity or expression of other R TKs, such as 
PDGFR or IGFlR (4) or the activity of AKT pathway (5). Cells adapt to the condition of 
suppression ofmB-Raf/MEK!ERK signaling by switching survival signaling to 
dependency on alternative pathways. 
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3-2. Results 
Establishment of PLX4032-resistant BRAF mutant melanoma cell sub-lines and 
their susceptibility to cell growth inhibition initiated by PKCo inhibition 
Although the B-Rafinhibitor PLX4032 (vemurafenib) was a great advance in 
melanoma therapy, development of resistance to the drug in most patients has been an 
ongoing challenge. Because one of the proposed models ofPLX4032 resistance involves 
the secondary mutation ofNRAS and because my initial studies revealed the 
effectiveness of PKC8 inhibitors in NRAS mutant cells, I next tested whether B 106 could 
be effective in those BRAF mutant melanoma cells that have become refractory to 
PLX4032. I established the BRAF V600E mutant melanoma cell sub-lines resistant to 
PLX4032 by continuously exposing A375 and SKMEL5 cells to PLX4032, with the 
concentrations gradually increased over weeks. The morphology ofPLX-4032 resistant 
cells (referred as "PLX-R") was flatter, and more enlarged and spindle-looking compared 
to their parental cells in both the A375-PLX-Rs and SKMEL5-PLX-Rs derivatives 
(Figure 22). Resistance ofPLX-Rs to PLX4032 was verified by comparing their 
sensitivity to the drug with that of their parental cells (Figure 23). PLX-R derivative lines 
from both A375 and SKMEL5 grow in the presence of concentrations ofPLX4032 which 
were cytotoxic to the parental cells, as assessed by MTS assay. 
B106 effectively inhibited cell growth ofboth A375-PLX-Rs and SKMEL5-PLX-
Rs, verifying the potency ofB106 in B-Rafinhibitor-resistant melanoma cells with 
BRAF mutation in addition to melanoma cells with NRAS mutations (Figure 23). The 
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specificity of this growth inhibitory effect on cell survival produced by PKC8 inhibition 
was confirmed by lack of the same effect by negative control compound B 154 (Figure 
23). In addition, proliferation of melanoma cells carrying BRAF mutations (the parental 
cells ofthe PLX-Rs) was also prevented by B106 (Figure 23). As discussed below, 
parental cells and PLX-R cells show differential behaviors in response to B106 treatment. 
Although B106 abrogates proliferation of both parental cells and PLX-R cells, it is 
possible that they undergo growth inhibition via distinct molecular mechanisms. 
Alternatively, our previous studies had shown that oncogenic mutation of CRAF makes 
non-transformed cells susceptible to PKC8 inhibition (1 0). It is also possible that the 
V 600E BRAF mutation may be similarly sensitizing the cells to growth inhibition by 
PKC8 inhibitors. 
Mechanism of resistance to a B-Raf inhibitor 
As a part of the scheme approach to better understand the actions of B 1 06, the 
mechanism of resistance ofPLX-R cells was studied. Genomic DNA was sequenced in 
the region flanking frequently mutated codon 61 of NRAS in order to examine whether 
development of resistance is the consequence of secondary NRAS mutations, as one of 
the proposed models of resistance has suggested. SBcl2 cells were found to possess 
Q61K mutations homozygously as predicted, validating the assay. The sequencing 
analysis demonstrated that neither of the A375-PLX-Rs or the SKMEL5-PLX-Rs had 
acquired a mutation in NRAS residue 61 (Table 3). 
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Subsequently, the activity of the endogenous Ras proteins was assayed to explore 
the possibility that aberrant Ras activity other than NRAS mutation was responsible for 
the acquired PLX4032 resistance, because aberrant activation ofRas proteins can result 
from a number of events other than genetic mutations in the RAS genes. Under 
physiological conditions, Ras proteins, when activated by extracellular signals and GTP 
bound, bind to the Ras-binding domain (RBD) in the Ras effector proteins. In this assay, 
activated Ras proteins were pulled down with an agarose-conjugated RBD peptide and 
detected by immunoblot analysis with antibodies against N-Ras or pan-Ras. As predicted, 
NRAS mutant SBcl2 melanoma cells and NIH-3T3 cells that were stably-transfected with 
NRAS-Q61K mutant (called "NIH-NRAS" below) showed high N-Ras activity, serving 
as positive controls for the assay system (Right panel at Row 1, Figure 24). The left 
panel in Row 1 showed slightly higher activity levels ofN-Ras in A375-PLX-R lines 
compared to A375 parent cells (Figure 24) . Row 2 panels were blotted for pan-Ras 
activity (K-Ras, H-Ras and N-Ras) and the left panel also suggests slightly elevated 
activation ofRas proteins in A375-PLX-Rs (Figure 24); however, further data is needed 
to confirm elevated Ras activity in these sub lines. 
Immunoblot analyses were next conducted under two conditions ofPLX4032 
exposure treatment to determine a pathway or molecules whose basal activity are altered 
in PLX-R cells and contribute to build resistance to PLX4032. PLX4032 was withdrawn 
from PLX-R cells for 48 or 72 hours in the first set in order to determine basal levels of 
activity or expression of the molecules in PLX-R cells that have previously been reported 
to be involved in mechanisms of resistance (left half in each cell series in Figure 25). The 
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second treatment condition compared the basal activity or expression levels ofPLX-R 
cells in the presence of the inhibitor to the response of parent cells to the drug (right half 
in each cell series in Figure 25). The parent cells were exposed to the drug for only 6 
hours to decrease cytotoxic effects which might confound interpretation. C-Raf was 
expressed at high levels in SKMEL5-PLX-Rs, whereas hyperactivation of C-Raf, as 
evidenced by phosphorylation, was observed in A375-PLX-Rs (Figure 25). Differences 
in AKT or B-Raf activation between parental cells and PLX-R cells were not observed. 
In addition, Figure 25 demonstrated that both SKMEL5-PLX-Rs remain responsive to 
ERK-MAPK pathway inhibition by PLX4032, and yet are capable of surviving under the 
drug-treatment conditions, indicating that these cells employ an alternative pathway for 
survival to compensate for mutant B-Raf/ERK inhibition by the drug. Conversely, A375-
PLX-Rs exhibited higher phosphorylation levels ofERK regardless of the presence or 
absence ofPLX4032 compared to parent A375 cells (Figure 25). Combined with the 
observation ofhyperactivation of C-Raf, the results imply that A375-PLX-R cells have 
overcome drug-induced inhibition of aberrant B-Raf activity after prolonged exposure to 
the drug and maintain their survival by bypassing B-Raf inhibition and switching over to 
C-Raf-mediated ERK signaling reactivation. 
As described in the chapter introduction, B-Raf selective inhibitors were reported 
to paradoxically activate the MEK/ERK pathway via C-Rafin RAS-mutant cells, leading 
to accelerated cell proliferation. This model was, indeed, confirmed in my NIH-NRAS 
cells as well: exposure ofNIH-NRAS cells to PLX4032 increased the phosphorylation 
level of ERK. In contrast, exposure to the MEK inhibitor UO 126 resulted in attenuated 
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ERK phosphorylation, compared to the vehicle-treated cells (Figure 26). U0126 
treatment decreased ERK phosphorylation in parental NIH-3T3 cells as well as NIH-3T3 
cells that were stably-transfected with BRAF-V600E mutant ("NIH-BRAF"), whereas 
only NIH-BRAF cells, but not parental cells which do not express oncogenic B-Raf 
decreased phospho-ERK level in response to U0126 (Figure 26). Indication of elevated 
Ras activity (Figure 24) and switched dependency from B-Rafto C-Raffor ERK 
signaling (Figure 25) in A375-PLX-R cells might provide a basis for a Ras/C-Raf-
mediated mechanism of resistance, at least in A375-PLX-R cells. 
Resistance to PLX4032 transforms the response of BRAF -mutated cells to resemble 
that of NRAS-mutant type with respect to H2AX activity 
As the JNK-H2AX cascade was shown to play an important role in B106-induced 
apoptosis in NRAS mutant melanoma cells (Chapter 2), the activation of JNK and H2AX 
was studied in PLX-R cells and their parental cells in response to B 1 06 treatment. A3 7 5 
parental and A375-PLX-R5 cells, and SKMEL5 parental and SKMEL5-PLX-R4 cells, 
were treated with B106 at two different concentrations (0.5 or 2J.1M) for two different 
durations (2 or 10 hours). 
An immunoblot analysis demonstrated that the basal level ofH2AX 
phosphorylation was elevated in both A375-PLX-R5 and SKMEL5-PLX-R4 cells 
(Figure 27). Furthermore, B 106 treatment consistently induced more robust activation of 
H2AX in these cells, in comparison to parental cells, in which H2AX activation 
following B106 treatment was not observed (A375 cells), or only slightly induced 
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(SKMEL5 cells) (Figure 27). These results from PLX-R lines derived from two 
independent BRAF mutant cell lines suggest that acquired resistance to PLX4032 may 
change the sensitivity of the cells to B106-induced H2AX phosphorylation, making their 
response more similar to the response of NRAS mutant melanoma cell lines. Considering 
that cell growth inhibition is induced in BRAF mutant melanoma cells as effectively as in 
NRAS mutant cells by PKCo inhibition (Figure 23), this might suggest that inhibition of 
PKCo causes cell growth inhibition through different molecular mechanisms in BRAF 
mutant cells and NRAS mutant cells, and acquired drug resistance in BRAF mutant cells 
might introduce the NRAS-mutant type mechanism to BRAF mutant cells. 
Interestingly, basal JNK activity was higher in A375-PLX-R5 cells than in A375 
parental cells, while SKMEL5 parental cells displayed more basal JNK activity than 
SKMEL5-PLX-R4 cells (Figure 27). This observation together with other published 
studies raises a hypothesis about a crosstalk between ERK and JNK, although it is 
beyond the scope of this dissertation project. This crosstalk is to be addressed in more 
detail in the discussion section below. 
PLX4032 and B106 together additively inhibit cell growth in melanoma cells with 
BRAF mutation 
Fundamentally, cancer recurrence resulting from drug resistance occurs because a 
small number of cells develop resistance to the therapy and survive the regimen to 
gradually proliferate into a recurrent cancer. Therefore, ideally, recurrence can be 
preventable if the first regimen could eliminate all the cancerous cells. Generally, the 
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dose of any drug required to do so might be far above the therapeutic window and 
produce serious adverse effects to normal cells, and ultimately, the entire body. In this 
sense, a combination therapy of multiple drugs could provide a more reasonable strategy 
if those drugs, at the doses within their therapeutic windows, together generate a greater 
anti-cancer effect with manageable adverse events. 
Based on this principle, therefore, the potential combinatorial application of B 1 06 
with PLX4032 in a regimen in melanomas with a BRAF mutation was explored. A375 
and SKMEL5 cells were plated at low cell density and treated with B106 or PLX4032 
alone or together for 8 days. Then, cell colonies, each of which was formed from an 
individual viable cell, were stained and quantified. Combinational use of B 1 06 and 
PLX4032 reduced the number of colonies from both A375 and SKMEL5 cells to a 
greater effect than B106 or PLX4032 alone, exhibiting a more extensive effect on 
irreversible cell growth inhibition (Figure 28). This experiment suggests the potential 
benefit ofB106 in combination with PLX4032 in melanomas with BRAF mutations, by 
further lowering the number of cells that survive the drug treatment and might eventually 
develop resistance to PLX4032. 
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A375 Parent SKMELS Parent 
A375-PLX-R3 SKMELS-PLX-R 1 
A375-PLX-R5 SKMEL5-PLX-R4 
Figure 22: Establishment of PLX4032-resistant BRAF mutant melanoma cell sub-
lines and morphological comparison between parent and PLX4032-resistant cells. 
To derive PLX4032-resistant sub-lines (referred as "PLX-R"), A375 and SKMEL5 cells 
were plated at low cell density and treated with PLX4032 at lf.!M or O.Sf.!M, respectively. 
Over the course of a 3-4 week period, the concentration ofPLX4032 was gradually 
increased up to 4f.!M (A375) or 2f.!M (SKMEL5) and clonal colonies were picked. 
Derived cells have been maintained in PLX4032-containing medium (lf.!M: A375-PLX-
Rs, O.Sf.!M: SKMEL5-PLX-Rs). Photographs were taken at the lower (left) and higher 
magnifications (right). 
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Figure 23: Resistance of A375-PLX-R and SKMELS-PLX-R cells to PLX4032 and 
effect ofPKCo inhibitors on cell survival. (Left) A375 parental and two A375-derived 
PLX4032-resistant cell lines, R3 and R5, (Right) SKMEL5 parental and two SKMEL5-
derived PLX4032-resistant cell lines, R1 and R4. To confirm resistance to PLX4032, the 
viability ofPLX4032-resistant cells and their parental cells was measured by MTS assay 
during treatment with PLX4032 (4)-!M: A375 and its derivatives, 1)-!M: SKMEL5 and its 
derivatives). To assess the effect ofPKC() inhibition, cells were treated with rottlerin 
(5)-!M) or B106 (l).!M) at the indicated times, and MTS assays were performed. DMSO 
and B 154 (2)-!M) served as a vehicle control and a compound negative control forB 106, 
respectively. Each point represents the average of triplicate and error bars indicate the 
standard deviations oftriplicates. P values(*) were calculated between DMSO (vehicle 
control) and rottlerin or DMSO and B 106 in each cell line at 72 hours (p < 0.0002). The 
experiment was repeated at least twice in each cell series. 
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NRAS BRAF 
Cell line Genomic A.A. Allele Genomic A.A. Allele 
mutation mutation mutation mutation 
A375 Parent - - - T1799A V600E Homo 
A375 PLX-R3 - - - T1799A V600E Homo 
A375 PLX-R5 - - - T1799A V600E Homo 
SKMEL5 Parent - - - T1799A V600E Hetero 
SKMEL5 PLX-Rl - - - Tl799A V600E Hetero 
SKMEL5 PLX-R4 - - - Tl799A V600E Hetero 
SBcl2 C181A Q61K Homo - - -
Table 3: Analysis of genomic NRAS mutations of A375-PLX-R and SKMELS-PLX-
R cells. Genomic DNA of A375 and SKMEL5 cells, and their derivative PLX4032-
resistant (PLX-R) sub lines were sequenced around the commonly mutated codon 61 in 
NRAS and codon 600 in BRAF. Resistant cell lines did not acquire secondary mutations 
at codon 61 in NRAS. The presence ofBRAF V600E mutation was also confirmed in 
these cell lines. 
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Figure 24: Analysis ofRas protein activity of A375-PLX-R and SKMELS-PLX-R 
cells. (Top) Activated Ras protein (GTP-bound) was pulled down from whole celllysates 
with agarose-conjugated Ras-binding domain (RBD) peptide, and detected by 
immunoblot analysis with N-Ras specific antibody (Row 1) or pan-Ras antibody (Row 
2). Levels of a-tubulin served as a loading control for input (Row 3). (Bottom) 
Immunoblotting oftotallysates was performed to confirm the basal level ofN-Ras 
expression. Levels of a-tubulin served as a loading control. This experiment was 
performed once. 
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Figure 25: Mechanism ofPLX4032 resistance. In the left three lanes of A375 and 
SKMEL5 samples, parental cells were maintained in normal medium (no PLX4032) for 
the entire period of experiment, whereas PLX4032 had been washed out of the medium 
for at least 48 hours in the A375-PLX-Rs and SKMEL5-PLX-Rs lines prior to lysis. In 
the right three lanes of the A375 and SKMEL5 samples, fresh PLX4032-containing 
medium (4f.!M: A375, 2f.!M: SKMEL5) was replaced with normal medium (no PLX4032) 
in parental cell plates and with PLX4032-containing medium in PLX-R cell plates 6 
hours before lysing. Protein lysates were subjected to immunoblotting for 
phosphorylation or total expression levels of the indicated proteins. Levels of 13-actin 
served as a loading control. This experiment was performed once. 
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Figure 26: Paradoxical activation of ERK by PLX4032 treatment in NIH-NRAS 
cells. NIH-BRAF and NIH-NRAS cells stably express mutant form ofB-RafV600E or 
N-Ras Q61K. These cells were established by stably-transfecting NIH/3T3 cells with 
BRAF V600E mutant or NRAS Q61K mutant expressing plasmid and selected by 
puromycin treatment (2.5f.!g/ml). The cells were treated with PLX4032 (2f.!M), U0126 
(5f.!M) or vehicle for 24 hours. Protein lysates were subjected to immunoblotting for 
phosphorylation or total expression levels of the indicated proteins. Levels of a-tubulin 
served as a loading control. PLX4032 preferentially inhibits the V600E mutant form of 
B-Raf. ERK phosphorylation was attenuated by PLX4032 treatment in NIH-BRAF cells, 
while NIH/3T3 parental cells which do not carry mutant B-Rafwere not susceptible to 
PLX4032. On the other hand, PLX4032 paradoxically increased the level ofERK 
phosphorylation in NIH-NRAS cells, consistent with previous reports. The MEK 
inhibitor U0126 reduced the level ofERK phosphorylation in all three cell lines. This 
experiment was performed once. 
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Figure 27: Activation ofH2AX by B106 treatment in A375-PLX-R5 and SKMELS-
PLX-Rl cells compared to parental cells. Cells were treated with B106 at the indicated 
concentrations for the indicated times. A375-PLX-R5 and SKMEL5-PLX-R4 cells were 
treated with B106 in the presence ofPLX4032 (4f.lM for A375 and its derivative, 2f.lM 
for SKMEL5 and its derivative). Protein lysates were subjected to immunoblotting for 
phosphorylation or total expression levels ofthe indicated proteins. Levels ofGAPDH 
served as a loading control. Both A375 PLX-R5 and SKMEL5 PLX-R4 cells had higher 
basal phosphorylation levels of H2AX compared to parental lines, and B 1 06 treatment 
induced more robust activation ofH2AX in both PLX-R cell lines than in parental cells. 
The experiment was repeated twice using A375 and A375-PLX-R5 and performed once 
using SKMEL5 and SKMEL5-PLX-R4. The same experiment was performed in 
SKMEL5 and SKMEL5-PLX-Rl as well, with the same results. 
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Figure 28: Additive irreversible effect of PLX4032 and B106 on cell viability in 
BRAF mutant cells. The same numbers of A375 and SKMEL5 cells were plated at low 
cell density and treated with PLX4032 (4J.LM: A375, 0.5J.LM: SKMEL5) or B106 (O.lJ.tM) 
alone or together for 8 days. DMSO served as a vehicle control. Cell colonies were 
stained with ethidium bromide for visualization and counting. Each point represents the 
average of duplicate and error bars indicate the standard deviations of duplicate. P values: 
** p:S0.05, * p<0.002. Combination treatment ofPLX4032 and B106 had an additive 
inhibitory effecte on the colony formation ability of the cells compared to treatment with 
PLX4032 or B106 alone. This experiment was repeated more than five times. 
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3-3. Summary 
In spite of the high response rate and initial tumor regression, PLX4032, a potent 
B-Raf inhibitor approved for melanomas carrying oncogenic BRAF-V 600E mutations, 
challenges remain: most patients relapse due to resistance to this drug and the drug is 
ineffective in the 40-50% of patients with melanomas lacking the mutation. In this 
chapter, the possibility of the potential application ofPKCo inhibition in PLX4032-
resistant melanomas, in addition to melanomas with NRAS mutation as studied in 
Chapter 1, was explored. First, PLX4032-resistant sub-cell lines ofBRAF-mutated cells 
A375 and SKMEL5 (termed as "PLX-Rs") were established by constantly exposing those 
cells to the drug. Proliferation ofPLX-R cells of both A375 and SKMEL5 was inhibited 
in the presence ofB106, indicating PKCo can potentially be a therapeutic target in B-Raf 
inhibitor resistant melanomas as well as in melanomas with NRAS mutations. Among the 
proposed mechanisms of resistance to B-Rafinhibitors, C-Rafhyperactivation appears to 
be the mechanism at least in A375-PLX-Rs possibly in the association with elevated Ras 
activity. Both A375-PLX-Rs and SKMEL5-PLX-Rs possess higher levels of basal H2AX 
activity, and induced more robust activation ofH2AX in response to B106 than their 
parental cell lines. This observation raises the hypothesis that acquiring B-Raf inhibitor 
resistance results in BRAF -mutated melanoma cells responding more similarly to NRAS-
mutated type cells in terms of their response to B 106 treatment. 
Furthermore, combinatorial treatment ofB106 and PLX4032 produced a greater 
effect on cell growth inhibition in melanoma cells with BRAF mutations, which suggests 
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that this combination therapy may have clinical benefit in delivering superior anti-
proliferation activity. 
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Discussion and Future Directions 
Overview of melanoma and current obstacles to effective therapy 
2011 was an exciting year in the history of melanoma treatment: the FDA 
approved the first two targeted therapies for metastatic melanoma, in which conventional 
treatment options have not made a significant improvement in patients' overall survival 
for decades. In particular, the impressively high response rates of over 50% produced by 
vemurafenib treatment appeared revolutionary. However, almost all responders who have 
experienced significant tumor regression from vemurafenib treatment relapse due to 
acquired drug resistance to the drug (7). Although B-Rafmutant tumors, one form of 
which (V 600E) is exclusively the target of vemurafenib, account for 50-70% of 
melanoma cases (4), B-Rafinhibitors alone do not represent the ultimate treatment for 
metastatic melanomas due to this issue of drug resistance. On the other hand, there has 
not to date been a targeted therapy for melanomas harboring NRAS mutations, the second 
most frequent genotype after BRAF, and MEK inhibitors currently in clinical trials are 
not likely to become an important option in NRAS-mutated melanomas due to their 
preferential activity against BRAF -mutated melanomas (even though they should 
theoretically be as effective in NRAS-mutated melanomas as BRAF-mutated melanomas) 
(3). This reality means that melanomas remain among the cancers that still await potent 
treatment options. In particular, melanomas with NRAS mutations and melanomas 
previously treated with B-Raf inhibitors represent an unmet medical need, as they 
constitute a large proportion of the melanoma cases. 
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B-Raf inhibitor resistance and its mechanisms 
B-Rafinhibitor PLX4032 (vemurafenib), one of the first two targeted therapy in 
melanoma, was a major advance in melanoma therapy. Although it achieves a remarkably 
high response rate and tumor regression in responders initially in treatment, tumors 
eventually and inevitably relapse due to the development of resistance to this drug. 
Several models have been proposed as to how cells acquire resistance to PLX4032: 1) 
reactivating MEK/ERK pathway through bypassing BRAF (via secondary mutation in 
NRAS, hyperactivation/overexpression of C-Raf, or activation of another MAPKK COT), 
or 2) adapting dependency on alternative pathways (hyperactivation or overexpression of 
receptor tyrosine kinases, such as PDGFR~ or IGFlR). Ironically, the complexity and 
redundancy ofRas signaling pathways that allow the cells to adjust the change in the 
surrounding environment with flexibility provide the tumor cells many opportunities for 
drug resistance. While not diminishing the importance of PLX4032 as a breakthrough 
drug, development of strategies to conquer or bypass the resistance has now become the 
next urgent task in the field, as has the development of therapies for category of 
melanomas that remain unaddressed: NRAS-mutated melanomas. Moreover, the potential 
risks ofthe use ofB-Rafinhibitor in RAS-mutated melanomas (84-87), and their 
potential to cause secondary tumors with RAS mutations (88, 89) further highlight the 
necessity to explore the mechanisms of action, resistance or influence of B-Raf inhibitors. 
To explore the potential of a PKCo-targeted inhibition therapeutic strategy, 
PLX4032-resistant cell lines were established from two individual BRAF-mutated 
melanoma cell lines. These sub lines can survive in the presence ofPLX4032 at 
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concentrations that effectively inhibit the growth of the parental lines (Figure 23). None 
of the PLX4032-resistant cell lines tested harbors a secondary genomic mutation in 
NRAS codon 61 (Table 3), but some sub lines showed the potential evidence of elevated 
activity of the endogenous Ras proteins (Figure 24). Furthermore, PLX4032-resistant cell 
lines demonstrated hyperactivationloverexpression of C-Raf, another isozyme in the Raf 
family (Figure 25). Previously, C-Rafwas demonstrated to mediate the activity of the 
ERK-MEPK pathway in RAS mutated cells, resulting in accelerated tumor cell growth 
(84-87). Considered together, the mechanism of resistance in the PLX4032-resistant cell 
lines established in this study might be the result of the hyperactivationloverexpression of 
C-Raf, in possible association with elevated Ras activity, at least in derivatives from one 
of the two cell resistant cell types. 
Apoptosis and chemotherapy 
Apoptosis or programmed cell death plays a critical role in the action of many 
anti-cancer drugs. Because apoptosis induces ordered disruption of the cell without 
leakage of cellular components and induction of inflammation, it is fundamental for 
development and regulation of tissue homeostasis whose alteration has serious 
consequences. For an anti-cancer therapy that aims selective toxicity to only tumorigenic 
cells without damaging neighboring normal cells, apoptosis is an ideal ultimate 
mechanism of action. There are two major forms of apoptosis. Extrinsic apoptosis is 
induced by extracellular signals/ligands bound to the death receptors that belong to the 
TNF/NGF family, while the intrinsic pathway is activated in response to stress conditions 
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including DNA damage or oxidative stress (61). In spite ofthe differences in initiation 
processes, apoptosis is executed in a complicated multistep cascade regulated by the 
balance between pro-apoptotic and anti-apoptotic effectors to ensure it happens only 
when needed to maintain the homeostasis with the surrounding environment. Caspases 
are at the center of apoptosis regulation. Early in the apoptotic sequence, initiator 
caspases ( caspases 8 or 9) are activated following the initiation of apoptosis, which in 
tum cleave and mature the downstream caspases, called effector caspases, such as 
caspases 3, 6 or 7, which then regulate further downstream apoptotic modulators (61). 
The most well-known apoptotic regulators, the Bcl2 family proteins, are divided into pro-
apoptotic members and anti-apoptotic members. Pro-apoptotic members mediate 
apoptosis by disrupting mitochondrial membrane integrity, either directly forming pores 
or indirectly by binding to mitochondrial channel proteins, while anti-apoptotic members 
prevent apoptosis by interfering with pro-apoptotic members (61). The Bcl2 family as 
well as lAPs also regulate the activity of caspases. Apoptotic cells undergo a series of 
morphological events: DNA fragmentation, nuclear and cytoplasmic condensation and 
formation of apoptotic bodies, small membrane-enclosed particles containing cellular 
components which are eliminated by neighboring cells or phagocyte. 
PKC() as a therapeutic target in melanoma with NRAS mutations and B-Raf 
inhibitor resistance 
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The rationale for a potential PKCo-targeted therapy against tumors with aberrant 
Ras signaling is based on prior reports. Firstly, PKC() was demonstrated to be non-
essential for the survival and proliferation of normal cells and PKCo-null animals 
develop normally and are fertile (11), providing a postulate that a therapeutic approach 
targeting PKC() would likely spare normal cells, but inhibit proliferation of cancerous 
cells whose survival depend on PKC() activity. Thus, this approach would provide a 
tumor-specific therapy. In contrast, PKCa and A, are required for normal development 
(60). In this respect, selectivity ofPKC() inhibitors against PKC() over other PKC 
isozymes is critical in the development of PKC() inhibitors. 
Second, inhibition of PKC() preferentially inhibited growth of cancer cell lines 
with genomic mutations in the RAS genes, oncogenic activation of Ras proteins, or 
aberrant activation ofRas signaling pathways (10, 58). The incidence of urethane-
induced lung tumors was 69% lower in PKCo-knockout mice compared with wild-type 
mice (90). All of these wild type mice that developed tumors had activating mutations in 
KRAS, while only 69% of PKCo-knockout tumors had KRAS mutations (90) . These 
studies proposed the possible correlation between PKC() inhibition and aberrant Ras 
activation in cancers. Oncogenic mutations ofRAS are prominent in many types of 
cancers with particularly high prevalence and mortality rates and approximately 30% of 
human cancers are estimated to harbor activating mutations in one of the three Ras 
isoforms (KRAS, NRAS and HRAS) (91). Taken together, these reports above underline 
the potential ofPKCo-targeted therapy as a cancer-specific therapy targeting tumors with 
RAS mutations or aberrant Ras activity, those types of tumors which are particularly 
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difficult to treat, such as pancreatic cancers, lung cancers, colorectal cancers and 
melanomas. One ofthe proposed mechanisms ofB-Rafinhibitor-resistance is the 
evolution of secondary mutations in NRAS, suggesting a potential link between B-Raf 
resistant melanoma and RAS mutations. 
Motivated by this background on PKCo and Ras, this dissertation project was 
aimed to assess the potential of PKCo as a therapeutic target in NRAS-mutant melanomas 
and B-Raf inhibitor-resistant melanoma potentially with secondary NRAS mutations, 
which remain insensitive to the currently available treatment options. The goals of the 
project were: 1) to examine the effect ofPKCo inhibition on the suppression of tumor cell 
growth in melanomas with NRAS mutations and B-Rafinhibitor-resistant melanomas; 2) 
to identify the molecular mechanism of tumor cell growth inhibition initiated by PKCo 
inhibition; and 3) to evaluate the efficacy of a novel PKCo inhibitor BJE6-1 06 (B 1 06), 
which has been developed in our lab, against these cancers (Figure 3, Table 1). 
The dissertation work supports the potential of PKC8 as a therapeutic target in 
melanomas. Cell proliferation assays demonstrated that inhibition of PKC8 suppressed 
cell growth in multiple melanoma cell lines with NRAS mutations (Figure 5). PKC8 
inhibitors were also demonstrated to be effective in PLX4032-resistant cell lines (Figure 
23). The cell lines tested included different types of amino acid substitution ofNRAS 
codon 61, the most frequently mutated codon at NRAS (Table 2), suggesting the effect of 
PKC8 inhibitors does not depend on a specific NRAS mutation for their activity (unlike 
B-Rafinhibitors, some of which are selective to only the most common mutation, 
V600E). B106, which showed 1000-fold selectivity against PKCo over PKCa in 
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preliminary in vitro kinase assay, was active at nano molar concentrations, ten times 
lower than for rottlerin (Figure 5). The suppression of tumor cell growth was shown to be 
induced through caspase-dependent apoptosis (Figures 8 and 9). These results in the cell 
culture system exhibited a great potential of PKC8 inhibitors as targeted agents, although 
the in vivo efficacy of B 106 is yet to be determined. 
JNK signaling in apoptosis and PKCo inhibition 
Comprising one of the three MAPK pathways, the JNK pathway is involved in a 
wide variety of critical cellular activities, including apoptosis and the DNA-damage 
response. The JNK pathway, initially discovered as a UV radiation-responsive signal (92, 
93), induces apoptosis in part through regulating the Bcl2 family members mentioned 
above. JNK activates pro-apoptotic BAD by phosphorylation at Ser 128, which keeps 
scaffold protein 14-3-3 from sequestering BAD (94, 95). Activated BAD binds the anti-
apoptotic Bcl2 members and prevents them from being activated (96). Direct 
phosphorylation of anti-apoptotic Bcl2 by JNK was shown to inhibit its activity (97, 98). 
JNK also regulates translocation of pro-apoptotic Bax to mitochondria for activation 
through phosphorylating 14-3-3, which prevents 14-3-3 from sequestering Bax. JNK-
induced cleavage ofpro-apoptotic Bid prevents activation ofBax (99-101). Alternatively, 
JNK also activates transcription of genes that regulate apoptosis. JNK phosphorylates 
components of activator protein 1 (AP-1 ), a transcription factor complex, including c-Jun, 
JunD or ATF2, which activate transcription ofpro-apoptotic facilitators, such as TNFa or 
Fas-L (death receptor ligands) or Bak (a pro-apoptotic Bcl2 member) (102, 103). 
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Furthermore, a series of recent reports proposed a role for phospho-H2AX in apoptosis 
downstream of JNK, as discussed below. Supporting the critical role of JNK in apoptosis, 
mouse embryonic fibroblasts with JNKl/2 knocked-down were resistant to apoptosis 
induced by various apoptotic stimuli (104). Many chemotherapeutic agents employ the 
JNK pathway for their anti-cancer activity, such agents including paclitaxel, cisplatin or 
doxorubicin (105, 106). 
In this dissertation project, activation of the JNK pathway was found to mediate 
caspase-dependent apoptosis induced by PKC8 inhibition. Among the previously-
reported substrates ofPKC8, activation of JNK was consistently induced by B106 
treatment, but other molecules, including the closely-related MAPKs p38 or ERK, were 
not activated (Figure 13). The effect ofPKC8 inhibition specifically on JNK was further 
confirmed by selective downregulation of PKC8 protein using PKC8-specific siRNA 
(Figure 16). Detailed pathway analysis demonstrated the cascade ofMKK4-JNK1/2-
H2AX is activated by B106 treatment (Figure 14). Furthermore, absence of JNK1/2 
expression in the cells significantly mitigated caspase activity induced by PKC8 
inhibition (Figure 18). These results imply the functional importance and necessity of the 
activation of this pathway in PKC8 inhibition-induced caspase-dependent apoptosis in 
NRAS mutant melanoma cells. 
While almost all studies that link PKC8 and JNK were reported in the context of 
the pro-apoptotic function of PKC8, one recent report demonstrated that knockdown of 
PKC8 induced apoptosis with increased phosphorylation of JNK in NIH-3T3 cells stably 
transfected with HRAS, consistent with my findings (47). In this report, knockdown of 
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PKC8 increased expression ofPKCa and~' which subsequently interacted with Rackl 
(an adaptor protein) to recruit INK to the complex, which induced an apoptotic response. 
Although it is encouraging to find this similar observation produced in independent 
systems, it should be noted that the assays employed in that report were entirely 
performed using siRNA. While RNAi-based studies have an advantage in elucidating 
molecule-specific functions in the cells; the biological consequences of down-regulating 
a protein target by RNAi do not necessarily mimic the effects of a small molecule 
inhibitor bound to the target. The results based primarily on RNAi should therefore be 
interpreted with caution if its goal is as proof-of-concept for the development of an 
inhibitor against the activity of the target molecule as a therapeutic (and this is indeed 
generally the ultimate plan for such type of studies). 
Crosstalk between ERK and JNK? 
A number of observations made during the course of this work also warrant 
further investigation. As mentioned in Chapter 3, Figure 27 showed an apparently 
conflicting observation between the A375 and SKMEL5 lines with respect to basal INK 
phosphorylation levels. Basal JNK activity was higher in A375-PLX-R5 cells than in 
A375 parental cells, while SKMEL5 parental cells displayed more basal INK activity 
than SKMEL5-PLX-R4 cells. The pattern was not associated with either PLX4032 
resistance or changes in basal expression level of H2AX phosphorylation between 
parental and PLX-R cells. Rather, it appeared to be correlated with the pattern ofERK 
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phosphorylation levels: that is, higher ERK activation level in A375-PLX-Rs and lower 
ERK activity in SKMEL5-PLX-Rs compared to the parental cell line of each (Figure 25). 
Interestingly, transient treatment with PLX4032 (B-Rafinhibitor) or U0126 
(MEK1/2 inhibitor) decreased the phosphorylation level of not only ERK but also JNK in 
A375 and SKMEL5 cells (Figure 29), although the known direct action of both 
compounds is to inhibit only the activation of ERK. Indeed, in vitro kinase assays of 
these inhibitors demonstrated a lack of inhibitory actions on JNK1/2/3 (78, 107). As 
therefore the observed inhibition of JNK phosphorylation is not a result of the direct 
action ofPLX4032 or U0126, this result means that transient inhibition ofERK 
signaling, by inhibitors against upstream B-Raf or MEK, results in inhibition of JNK 
activity by an unidentified mechanism. 
Constitutive activation of MEK/ERK signaling was reported to enhance JNK 
activity in melanoma, by "rewiring" or causing crosstalk between the ERK and JNK 
signaling pathways (108). In that report, constitutively-high levels ofERK activity 
resulting from aberrant activity of upstream components (B-Raf or N-Ras) in melanoma 
increased transcription and stability of c-Jun through CREB or GSK3. The regulation of 
c-Jun by ERK pathway was not observed in the cells without constitutively-high ERK 
signaling. Subsequently, c-Jun increased transcription of target genes, including RACK1, 
an adaptor protein that serves a platform for PKCs to phosphorylate JNK and this 
provided a positive feedback loop between c-Jun and JNK, which further enhanced the c-
Jun activity. My current results support this model of crosstalk from ERK to JNK 
signaling. 
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Although that report picked the cell lines studied based on their high levels of 
ERK signaling and the presence of genomic mutation (BRAF or NRAS), the cell lines 
were established from the tumors harvested from different patients with distinct genetic 
background. In my studies, PLX-Rs and their parental cell lines can serve pairs of cell 
lines that differ from each other minimally in terms of genetic makeup, certainly less than 
melanoma lines derived from different tumors, so examination of their responses to drugs 
may be informative. In Figure 25, higher ERK activation level compared to parental cells 
in A375-PLX-Rs indicates the PLX-Rs overcame the inhibitory activity ofPLX4032 and 
reactivated Raf/MEK/ERK signaling, whereas lower ERK activity in SKMEL5-PLX-Rs 
suggests they still maintain a susceptibility to PLX4032 and survive constant PLX4032 
exposure by employing an alternative survival pathway independently of ERK signaling. 
Thus, A375-PLX-Rs represent the cells with constitutively-elevated levels ofERK 
signaling in comparison to parental cells. In A375-PLX-R cells with high ERK activity, 
basal JNK phosphorylation level is also persistently elevated, in contrast to A375 parental 
cells which have lower ERK activity (Figure 27). 
Collectively, these observations and the published report together produced the 
hypothesis on a possible crosstalk between ERK and JNK (Figure 30): temporary 
inhibition of the Raf/MEKIERK pathway leads to inhibition of JNK activation in BRAF 
mutant melanoma (represented by A375 and SKMEL5), while those cells that have 
overcome the condition of long-term inhibition of Raf/MEK/ERK signaling and acquired 
constitutively-high levels ofERK activation might consequently generate higher 
activation levels of JNK by employing a crosstalk mechanism from ERK to JNK 
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(represented by A375-PLX-Rs). The cells that did not acquire the condition of 
constantly-high ERK activation level still maintain the normal level of basal JNK 
phosphorylation (represented by SKMEL5-PLX-Rs). 
Dual function of phospho-H2AX- DNA repair and apoptosis 
H2AX, histone H2A variant X, is actually a minor subtype of the H2A family. 
Approximately 10% of histone H2A proteins are H2AX in normal fibroblasts, although 
the proportion varies in different tissues (up to 20%) (109). H2AX in its phosphorylated 
form (phospho-H2AX, also called yH2AX) is primarily known for its role in DNA 
double strand breakage (DSB) repair, and has long been utilized as an indicator of DSB. 
Upon DSB formation, PBK-like kinases, ataxia telangiectasia mutated (ATM), ataxia 
telangiectasia and Rad3-related (ATR) and DNA-dependent protein kinase (DNA-PK), 
are activated and phosphorylate H2AX at Ser 139 (110). Phosphorylated H2AX is one of 
the first proteins recruited to DSB sites during DNA damage response, and facilitates the 
access of repair proteins to the site (110). H2AX also participates in DNA damage-
induced chromatin remodeling by promoting the recruitment of remodeling complexes 
and/or other histone modifying protein complexes. 
In the context of apoptosis, the earlier studies reported that H2AX 
phosphorylation occurs as a consequence of apoptosis. DSBs generated from DNA 
fragmentation during the apoptotic process were reported to produce phosphorylated 
H2AX (71 ). DNA-PK and A TM were shown to be responsible for the phosphorylation of 
H2AX in this process (111). However, a series of recent studies instead proposed a more 
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active role ofphospho-H2AX in induction ofapoptosis. In this scenario, phosphorylation 
ofH2AX at Ser 139 provokes apoptosis by inducing DNA fragmentation in UV-damaged 
cells (70). Supporting this model, several studies reported phospho-H2AX-mediated 
apoptosis, some of which are involved in apoptosis induced by chemotherapeutic agents 
(73-76). Interestingly, immunofluorescent staining demonstrated a different distribution 
pattern ofphospho-H2AX between the events ofDSB and apoptosis (72). Phospho-
H2AX was distributed throughout nuclei in apoptosis, whereas DSB-localized phospho-
H2AX displayed a foci-specific pattern. Controversially, however, a pan-nuclear staining 
pattern ofphospho-H2AX was also reported to characterize DNA single-stranded regions 
induced by ultraviolet C radiation, in which case H2AX is phosphorylated by ATR (109). 
PKCo inhibition by B 106 treatment evoked phosphorylation of H2AX subsequent 
to JNK activation (Figures 14 and 15). Knockdown ofPKCo using siRNA supported this 
observation: JNK phosphorylation occurred by 24 hours after siRNA transfection and 
H2AX phosphorylation was observed at 72 hours after transfection (Figure 16). The 
phosphorylation of H2AX induced by B 106 treatment was mitigated in the absence of 
JNK expression, suggesting H2AX phosphorylation occurs downstream of JNK in case 
ofB106 exposure (Figure 17). Caspase activation caused by B106 treatment was 
significantly decreased in the absence ofH2AX expression. Furthermore, as a direct 
evidence of apoptosis, DNA fragmentation was almost completely abrogated with 
knockdown ofH2AX prior to B106 treatment (Figure 20). Collectively, these results 
demonstrate the importance ofH2AX as an active apoptotic mediator, with functional 
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evidence showing it to be a necessary component of apoptosis initiated by PKCo 
inhibition. 
B-Raf inhibitor resistance and similarity to NRAS type 
As described above, the analysis of resistance mechanism to PLX4032 showed a 
potential induction of the Ras/C-Rafpathway, upon which cells depend in order to 
survive the condition of constant inhibition ofB-Raf activity by PLX4032. The possible 
Ras/C-Rafmediated resistance mechanism implied a resemblance between PLX4032-
resistant cells and NRAS-mutated cells in their behaviors. Compared to parental cells, 
PLX4032-resistant cells exhibited higher levels of basal phospho-H2AX expression and 
more robust activation of H2AX in response to B 106 treatment (Figure 27), as was seen 
in melanoma cells with NRAS mutations (Figures 14 and 15). These observations imply 
that resistance to PLX4032 potentially transforms BRAF -mutated cells into "NRAS-
mutant type", at least with respect to basal levels ofH2AX activity, and in response to 
B106 treatment. Finally, combination treatment ofB106 and PLX4032 in BRAF-mutated 
melanoma cell lines provided at least additive anti-proliferative effects, and might inhibit 
the development ofPLX4032 resistance. 
Future Studies 
Although work detailed in this dissertation clearly established the potential of 
PKCo as a therapeutic target in melanomas, and the molecular mechanism of the action 
of PKCo inhibition, there are several areas remaining to be explored before this targeted 
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approach can be further developed as a therapeutic modality. First, the selectivity of 
B 1 06 as a PKCo-selective inhibitor needs to be assessed in more extensive in vitro kinase 
assays, in which B 106 is tested against a panel of kinases. While the assays performed in 
this project using siRNA strongly supported selectivity ofB106 against PKCo, it is still 
necessary to clarify the potential off-target kinases to better understand its actions, as 
such information might help predict possible side effects. Second, as mentioned earlier, 
in vivo efficacy needs to be confirmed when an improved B 1 06 analogue becomes 
available. Alternatively, it is also useful to consider methods to enable delivery ofthis 
extremely hydrophobic compound to the tumor in vivo, instead of modifying the 
compound structure itself. Also, the effect of B 106 in normal or non-tumorigenic cells, in 
this case normal melanocytes, has to be assessed to ensure its tumor-specificity, an 
essential characteristic of a potent anti -cancer therapy. In terms of further analysis of the 
PLX4032-resistance mechanism, resistant cells showed slightly elevated Ras activity, but 
this requires further validation. Among the possible assays to verify it, thorough analysis 
of genomic mutations in all of the RAS genes could be carried out, as there is the 
possibility that the elevated Ras activity is due to activating mutations of other RAS 
genes (KRAS or HRAS) or mutations at sites other than codon 61 (another frequently 
mutated codon is G 12). Mutations of codon 12 are more common in KRAS, and HRAS 
mutations are divided almost equally between codon 12 and codon 61 (112). Although 
genomic mutation at codon 61 in NRAS is more commonly observed in melanoma (91), 
the occurrence of secondary mutations in KRAS or HRAS in the resistant lines is 
possible because cancerous cells sometimes survive under condition of drug treatment by 
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selection for mutations providing an alternative means of survival (HRAS was more 
commonly mutated than other RAS genes in secondary cutaneous squamous-cell 
carcinomas tumors in patients with melanomas treated with vemurafenib (88)). 
"Marker" for action of PKC() inhibitors 
Another future direction of this project would be to identify markers that allow 
identification of the type of cancers in which B 1 06 or prospective PKC8 inhibitors would 
perform effectively and selectively. 
Melanoma is fundamentally well-suited for a therapeutic strategy pursuing cancer 
cell specificity by selection of a drug target molecule due to the frequency of "cancer 
cell-specific markers" (i.e., BRAF or NRAS mutations) or "cancer cell-specific events" 
(i.e., hyperactivation of the Raf/MEK pathway). Selectivity against cancer cells is already 
assured by the selection ofthe drug targets in case ofB-Rafinhibitors that selectively 
inhibit mutant form ofB-Raf or MEK inhibitors whose sensitivity is more prominent in 
the cells with BRAF mutations. As reasonable as the rationale behind the strategy 
actually is, however, targeting certain cancer cell-specific markers such as BRAF appears 
to provide facile opportunities for the cancer cells to develop drug resistance despite the 
sometimes remarkable antitumor activities produced early in the course of the treatment. 
While the complexity of Ras downstream signaling allows cells to have flexible and 
timely positive- or negative-functional regulatory options in response to changing 
environmental signals, it also provides for redundancy among these pathways, so that 
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cells can develop alternative mechanisms to compensate for any failure of the original 
signaling pathway, and it will remain the challenge for this type of therapeutics. 
On the other hand, it is more difficult for therapeutics whose targets are not 
"cancer cell-specific markers" or "cancer cell-specific events", to assure cancer 
specificity by their targets themselves. For this reason, the synthetic lethal approach has 
been, attracting an attention, as it provides cancer specificity without general cytotoxicity. 
Indeed, this is why this project started with the focus on melanomas with NRAS 
mutations being a "cancer cell-specific marker" and therefore synthetic lethal partner for 
PKC8, inspired by previous reports. However, harboring genomic mutations in RAS 
genes or aberrant Ras activity may not be the relevant marker for response to B 1 06, as 
B 106 was revealed to be equally effective on suppression of cell growth in melanoma cell 
lines with BRAF and NRAS mutations. Although such a marker that can predict the 
response to B 106 has not been identified at this point, this dissertation may be able to 
suggest markers to predict the mechanism of apoptosis that is induced under B 106 
treatment. Preliminary data showed the expression of total PKC() protein was less 
abundant in NRAS mutant cells and A375- and SKMELS-PLX-Rs than in A375 and 
SKMELS cells (Figure 31). On the contrary, basal phosphorylation level ofH2AX was 
higher in melanoma cells with NRAS mutation and A375- and SKMELS-PLX-Rs than in 
A375 and SKMELS cells (Figures 27 and 31). In NRAS-mutated cells and PLX4032 
resistant cells, B106 treatment appears to induce more robust response in terms ofH2AX 
activation than in A375 and SKMEL5 cells (Figures 14, 15 and 27). If higher activation 
levels of H2AX following B 1 06 treatment is actually correlated with the mode of cell 
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growth inhibition (thus, H2AX-dependent apoptosis) and lower H2AX activation with 
H2AX-independent apoptosis, the observation ofthe basal expression levels ofPKC8 or 
phospho-H2AX may be worth further investigation as the predictors of apoptosis after 
PKC8 inhibition. In order to verify such a correlation, however, much more extensive 
investigation is required, such as verifying the differential mode of apoptosis (H2AX-
depdent or independent) between high H2AX responder and non/low H2AX responders, 
and applicability of this "marker" in types of cancers other than melanoma. Interestingly, 
imatinib mesylate, a protein kinase inhibitor, has been shown to trigger apoptosis in 
gastrointestinal stromal tumor cell lines through upregulation of H2AX and imatinib-
mediated H2AX up-regulation correlated with imatinib sensitivity (75). 
Since there is a possibility that B 1 06 exerts apoptosis via distinct molecular 
mechanisms in BRAF-mutated cells compared to NRAS-mutated and B-Rafinhibitor-
resistant cells, based on H2AX activation status, the prediction of the apoptosis 
mechanism, at least, may be helpful to predict the possible side effects related to the 
elevated H2AX activation. To aim for the better clinical application in the future, 
nonetheless, it would be beneficial to fmd "a marker" to predict the efficacy of 
compounds like B106 and tumor selectivity and this could be a next step beyond this 
dissertation and project. 
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Figure 29: Inhibition of the Raf/MEK/ERK pathway transiently decreases JNK 
phosphorylation in A375 and SKMELS cells. A375 cells were treated with PLX4032 
(2J.!M) or vehicle (DMSO) for 2 hours, and SKMEL5 cells were treated with PLX4032 
(0.5J.!M), U0126 (5J.!M) or vehicle (DMSO) for 14 hours, or B106 (0.5J.!M) for 2 hours. 
Protein lysates were subjected to immunoblot analysis for phosphorylation or total 
expression levels ofthe indicated proteins. Levels of a-tubulin or GAPDH served as a 
loading control. The experiment was performed once for each cell line. 
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Figure 30: Hypothesis of crosstalk between ERK and JNK. (Left) Transient inhibition 
ofERK signaling by B-Rafinhibitors or MEK inhibitors inhibits JNK activation as well. 
(Right) By constant inhibition ofERK signaling, cells develop a resistance mechanism to 
overcome the inhibition and reactivate ERK signaling. In this case, constantly high levels 
of ERK activation lead to constantly high levels of JNK activation. On the other hand, 
those cells that did not acquire a resistant mechanism to the constant ERK inhibition still 
maintain their sensitivity to ERK inhibitors. As a result, the basal level of JNK activation 
remains normal. 
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Figure 31: Comparison of basal expression levels ofPKCo and phospho-H2AX in 
melanoma cells lines. (A) Protein lysates from BRAF mutant cells A375 and SKMEL5 
cells and their derivative PLX-R cells, and SBcl2 cells were subjected to immunoblot 
analysis for total expression levels of PKCo. Levels of a-tubulin served as a loading 
control. The experiment was repeated twice. (B) Protein lysates from NRAS mutant cells 
(SBcl2, FM6 and WM1366), BRAF mutant cells (A375, SKMEL5 and SKMEL28) and 
NIH/3T3 and their derivatives (NIH-NRAS and NIH-BRAF) were subjected to 
immunoblot analysis for phosphorylation or total expression levels of the indicated 
proteins. Levels of GAPDH served as a loading control. The experiment was performed 
once. 
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